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Abstract 
Cisplatin is the first and most widely used platinum-based chemotherapy drug and is the cornerstone 
agent in treating a broad spectrum of cancers, including ovarian cancer, testicular cancer, cervical 
cancer, bladder cancer, lung cancer, head and neck cancer, lymphoma, and brain tumors. It is one of 
the few curative anti-cancer agents; however, its clinical application is often limited by severe toxic 
side effects and resistance possessed by some cancers.  
    Our group has recently, through the femtomedicine approach, unraveled a new molecular 
mechanism of Cisplatin.  It has been found that Cisplatin is extremely effective for the dissociative 
electron transfer (DET) reaction with weakly-bound electrons to produce reactive radicals that cause 
DNA strand breaks, apoptosis, and final clonogenic cell kill. 
    Based on this DET mechanism, it is proposed that Cisplatin may be administered in combination 
with a biological electron donor to enhance its chemotherapeutic efficacy. We have tried a few 
combinations of Cisplatin and electron-donating compounds. In this thesis, we show results of the 
combination: Cisplatin and Rhodamine-B, the one with the greatest potential as demonstrated in both 
in vitro assays and in vivo xenograft mouse cancer models. This thesis begins with an introduction to 
cancer and cancer therapies in Chapter 1, where the theory, objective, and scope of this thesis are 
introduced. Chapter 2 focuses on some new understandings of Cisplatin-induced DNA damage. In 
vitro and in vivo experiment results on the effectiveness of the combination of Cisplatin and 
Rhodamine-B are presented in Chapter 3 and Chapter 4, respectively. In Chapter 5, time-resolved 
femtosecond laser spectroscopic studies on the reaction between Cisplatin and Rhodamine-B are 
shown. Chapter 6 as the last Chapter summarizes results obtained in this project and proposes some 
possible future research.  
  iv 
    In vitro experiments confirm the potential of this proposed combination of Cisplatin and 
Rhodamine-B to treat cancer. From cell survival tests, by applying MTT assays and clonogenic 
assays, it has been shown that our proposed combination significantly enhances the cell-killing 
efficacy in cancer cells; but surprisingly, not in normal cells. Besides, plasmid DNA gel 
electrophoresis and γ-H2AX staining in treated cells indicate that more double-strand breaks can be 
induced using our combination, compared to Cisplatin only. In addition, measurements on Caspase 
3/7 activation and Annexin V-FITC labeling flow cytometry experiments clearly show a significant 
enhancement in the population of apoptotic cells using our combination. To further verify the 
effectiveness of the combination of Cisplatin and Rhodamine-B, in vivo xenograft mouse models 
have been developed. Our combination greatly enhances the tumor growth inhibition and even tumor 
shrinkage in three different mouse models. Acute toxicity analysis and body weight measurements do 
not show additional side effects induced by the addition of Rhodamine-B. Lastly, spectroscopic 
measurements have confirmed that Cisplatin and Rhodamine-B can react, and the reaction is an 
electron transfer reaction. 
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Chapter 1 
Introduction 
1.1 Cancer 
In Canada and the United States cancer is becoming the leading cause of death. About 40% of Canadians 
will develop cancer in their lifetime, and about 25% of Canadians will die of cancer. It has been estimated 
that 202,400 Canadians will develop cancer in 2016 and 78,800 of them will die of cancer1; the 
corresponding estimated numbers are 1,685,210 and 595,690 in the United of Sates in 20162. Cancer has 
become a major worldwide public health issue. According to the National Cancer Institute (NIH), within 
the next two decades, 22 million people in the world will develop cancer. Cancer research is getting more 
and more important and pressing.  
1.1.1 Understanding of Cancer 
The fundamental cellular division and DNA replication mechanisms sometimes fail, compromising the 
genome integrity, and result in cancer formation3. Cancer is identified as genetic: it is a group of diseases 
that are extremely complex. Six hallmark biological capabilities of cancer, which describe the 
organization and complexity of neoplastic diseases, were proposed in 2000 by Hanahan and Weinberg4 
(Figure 1-1). These are: sustaining proliferative signaling, evading growth suppressors, resisting cell 
death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. 
Two other hallmarks were added to the list a decade later: reprogramming of energy metabolism and 
evading immune destruction5. Additionally, the concept of “tumor micro-environment” is introduced, and 
is exhibited by the specific tumor structure5.  
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Figure 1-1: Cancer hallmarks4. 
 
    Technologies have advanced our understandings of cancer. It has been known that for a specific cancer, 
cancer cells are not identical because of various genetic alterations and tumor micro-environment6,7. 
Cancer cells have subpopulations like the cancer stem cells that have been identified8. Cancer cells are 
heterogeneous. This nature makes the treatment of cancer even more challenging9. Besides, cancer cells 
can evolve via the communication between cells. Cells have been shown to exchange biomolecules such 
as proteins, lipids, and nucleic acids, by the release and uptake of extracellular vesicles (EVs)10. Recently, 
extracellular exchange of signals has been demonstrated among tumor cells in living mice11. Using the 
high-resolution intravital imaging and a Cre recombinase-based method, the study provided the first direct 
evidence in vivo of the exchange of active biomolecules between cancer cells. The researchers directly 
visualized the	 EVs released from more malignant MDA-MB-231 cells to less malignant cells. It was 
observed that by taking up these EVs, less malignant cells became more migratory and metastatic.  
    Understanding metabolism is also crucial. Cancer is life threatening. It has been shown that 
approximately 30% of late-stage patients die not only from the tumor itself, but also from cancer-
associated cachexia (CAC)12,13. Recently, two studies have been conducted in fruit flies showing that a 
  3 
protein secreted by tumor cells blocks insulin signaling, which results in organ wasting that accounts for 
~20% of cancer deaths14,15.  
    The study of cancer is expanding from the cellular level to the tumor microenvironment, and to the 
whole system.		
	
1.1.2 Causes of Cancer 
Cancer can be caused by both intrinsic factors like inherited mutations, hormones, immune conditions and 
mutations from metabolism, and external factors like tobacco, infectious organisms, chemicals and 
radiation16. To date, factors that are	 correlated with the occurrence of three types of cancer have been 
identified: skin cancer, lung cancer, and cervical cancer.  
    From the 1930s to the 1970s, after researchers discovered that tobacco-smoking can cause cancer, the 
lung cancer incidence rate decreased dramatically due to public awareness17 of this link. Quitting smoking 
can effectively prevent lung cancer. Radon exposure has also drawn much attention as the second leading 
cause of lung cancer18. It has been estimated that approximately 650 lung cancer deaths per year are 
prevented in the United States due to radon mitigation and prevention measures. In the area of skin cancer 
research, it has been found that UV radiation can damage skin19,20 and it has been estimated by the Cancer 
Council NSW that ~95% of melanomas and ~99% of non-melanoma skin cancers are caused by UV 
exposure. Although the numbers might vary by institutes, the causality is certain. Skin cancers are almost 
completely preventable by minimizing UV exposure through various measures such as using sunscreen.  
    Recently, the correlation between virus infection and cancer has drawn much attention and some new 
messages have been delivered. Human papillomavirus (HPV), a ubiquitous pathogen that will affect 
almost everyone at some point in their lives, is responsible for 99% of cervical cancers, and a small 
proportion of genital cancers. Since this discovery, three HPV vaccines have been developed and 
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manufactured, and they are now commonly given to teenage girls, and even boys. The story does not end 
here: in 2005,	 Gillison analyzed the samples she had collected for seven years from 300 participants: she 
found that head and neck cancer patients were 15 times more likely to be infected with HPV in their 
mouths or throats than healthy people21. Earlier Gillison also demonstrated that HPV could integrate its 
DNA into the nuclei of throat cells and produce potent oncoproteins22. Her later studies also showed that 
HPV-positive and HPV-negative oropharyngeal cancers had different risk profiles; as a result, they should 
be considered as two different diseases23 and therefore be treated differently24. A further question was 
asked: “if HPV can get into the mucous membranes of the mouth and throat, where does it stop?”25 
Studies	were conducted to investigate if HPV is correlated with lung cancer incidence. Current data do not 
affirmatively support this correlation: some studies have shown the existence of HPV DNA is more likely 
in lung tumors compared to healthy samples26,27 and concluded “HPV is the second most important cause 
of lung cancer after cigarette-smoking”, while some did not28. If the correlation between HPV infection 
and more other forms of cancers is confirmed, to save more lives, HPV vaccines should be given to a 
larger population and not restricted to young girls.  
    The public is also concerned if low-dose radiation from sources such as cellphones or medical exams is 
a carcinogenic factor. It has been shown that the amount of radiation is indeed increasing, but the 
correlation is very difficult to confirm29.  
 
1.1.3 The Best We Can Do: Early Cancer Diagnosis and Prevention 
Early diagnosis is crucial because cancers in their early stages are more likely to be curable. Taking lung 
cancer as an example, an early diagnosis (before any symptoms) gives patients an 88% chance of living 
for another decade30; and it has been shown that low-dose computed  tomography (CT) screening reduces 
lung cancer death by 20%31. Other cancers like ovarian cancer32 and pancreatic cancer33 have extremely 
high mortality that is largely attributed to the failure and/or difficulty of early diagnosis. More than 70% 
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of ovarian cancer patients are diagnosed with advanced disease32; the 5-year survival of which is only 20-
30%, compared to a 70%-90% cure rate of early stage patients (confined to the ovary)34. More than 80% 
of pancreatic cancer patients are diagnosed with distant metastasis35, at this late stage primary tumors have 
been unresectable. In the clinic, exocrine pancreatic cancer has the lowest survival rate among all cancers: 
74% of patients die within the first year after diagnosis and 94% of patients die within five years33. 
However, if patients could be diagnosed at stage I, the four-year survival rate is dramatically increased to 
higher than 75%36.  
    Researchers are working on developing diagnostic methods that are applicable, sensitive, accurate, and 
non-invasive. A recent study of secreted exsomes37 shows the possibility of early detection of some cancer 
types, including pancreatic cancer and breast cancer. Exsomes, lipid-bilayer-enclosed extracellular 
vesicles38 often contain important bio-information in the form of proteins and nucleic acids39. That study 
identified glypican-1 (GPC1), a cell surface proteoglycan as enriched in exsomes from cancer cells. GPC1 
can be detected in patients’ serum and its level is associated with tumor burden and survival. Additionally, 
serum sample test is simple and non-invasive. In recent efforts, massive population screening is advocated 
for breast cancer by regular mammography. Besides, women who carry a deleterious mutation in the 
BRCA gene will have a higher risk of developing breast cancer and ovarian cancer40. Biological kits are 
now commercially available to detect this mutation by simply sending companies a small bottle of saliva 
sample. Early cervical cancer detection is possible by routine Papanicolaou (Pap) test, named after Dr. 
Georgios Papanikolaou. This cytology-screening test has so far been the most successful cancer-screening 
test in history. However, the Pap test is unaffordable in some developing countries and an alternative is 
using acetic acid to perform visual inspection of the cervix (VIA: visual inspection with acetic acid) to 
reduce costs41. Also, biomarkers are targets to be detected for cancer diagnosis. By the nature of cancer 
formation, gene alterations should have taken place before a normal cell becomes cancerous. Taking 
colon cancer as an example, accumulated gene changes have been confirmed in the cancer forming 
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process42–44. This process provides an opportunity to detect cancer at an early stage or even before it 
occurs. Individuals with adenomatous polyposis coli (APC) gene mutations will get colon cancer in the 
future at a risk of almost 100%, and 60% of colorectal carcinoma patients carry this mutation45,46. 
Polymerase chain reaction (PCR) makes the mutation possible to be detected. Mutations in oncogenes 
such as K-ras (an early appearance)47,48 and tumor suppressor genes such as p53 (a later event)49,50 are 
also targets for the detection of colon cancer46. Advanced pancreatic cancer is extremely lethal; therefore, 
developing clinically possible early detection methods is of great importance. MicroRNAs, non-coding 
short RNAs (17- to 25-nucleotide-long) that regulate ~30% of human genes51, have been recently found to 
play crucial roles in cancer formation and metastasis52,53. Similar to a coding gene, a microRNA may act 
as a tumor suppressor as well as an oncogene if its function is lost/altered, and as a result a normal cell 
may be transformed to a malignant one52,54. Recently a study was conducted to identify if microRNAs in 
the whole blood can be used to detect pancreatic cancer55. It compared the expression of microRNAs in 
the whole blood of pancreatic cancer patients and healthy people. It was found that 38 microRNAs were 
possible biomarkers which can differentiate pancreatic cancer patients from healthy participants, and it 
also suggested two diagnosing panels, using a combination of multiple microRNAs to diagnose pancreatic 
cancer. The application of microRNAs’ expression detection is beneficial not only for early and accurate 
detection of cancer but also for therapeutic strategies and prognosis54.  
    According to the World Health Organization (WHO), at least one third of cancers can be prevented by 
quitting smoking, regular physical activity, healthy diet, prevention of infection, etc56. Finding ways to 
prevent cancer largely depends how well we understand cancer causes. The cervical cancer vaccine is a 
perfect example. 
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1.2 Cancer Therapies 
1.2.1 Surgery 
Cancer surgery is an operation to remove the tumor with some surrounding tissues including lymph 
nodes. Surgery can be preventive, reconstructive, palliative, and curative; it can also be a process to 
diagnose, stage, and de-bulk57.  
    Surgery is the oldest cancer treatment and it remains the major treatment for many types of cancer. 
Surgery can be curative when the tumor is localized and it is often combined with chemotherapy and/or 
radiation therapy. Now minimally invasive surgery is preferred, such as laparoscopic surgery, laser 
surgery, cryosurgery, microscopically controlled surgery, and endoscopy57. Robotic surgery is the newest 
technique in cancer surgery and it is achieving success in treating solid tumors such as lung cancer58–60. 
The da Vinci Si robotic system allows the surgery to be more visual and more precise; in addition, it 
provides quicker patient recovery.  
 
1.2.2 Radiation Therapy 
Radiation cancer therapy is the therapy utilizing ionizing radiation to kill cancer cells and/or to shrink 
tumors. The development of radiation medicine has four eras61, as shown in Figure 1-2. From the 
discovery to the successful application of x-ray in treating cancer, from knowing little about its biological 
activity to a precise management of radiation dosage and schedule, it has taken more than 100 years, and 
is still ongoing.   
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Figure 1-2: Revolution of radiation therapy. 
    The major target of radiotherapy is DNA, and the anti-cancer effect of ionizing radiation is generally 
thought to be a consequence of chemical modification of DNA62–64. Both of the two forms of ionizing 
radiation, electromagnetic and particle radiation are used in cancer treatment.  
 
1.2.3 Targeted Therapy 
Targeted therapy, as its name indicates, is a therapy that targets the difference in cell growth between 
cancer cells and normal cells; in this way, targeted drugs can selectively kill cancer cells without inducing 
severe side effects as traditional chemotherapies usually do. The most essential difference between cancer 
cells and normal cells is the difference in DNA; as a result, their produced proteins are different. 
Conventional targeted therapy focuses on unique/over-expressed proteins that are involved in cancer cell 
growth.  
    Currently, targeted therapy medicines include enzyme inhibitors, apoptosis-inducing drugs, 
angiogenesis inhibitors, etc65. Gefitinib is a drug that targets the epidermal growth factor receptors 
(EGFR), which are over-expressed in some cancers66. Gefitinib can block the signal from binding to 
EGFR and therefore to slow/stop cancer cell growth. Non-small-cell lung cancer has sensitive alterations 
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in EGFR and it has been shown very responsive to Gefitinib (a much better response compared to the 
standard carboplatin-paclitaxel chemotherapy group)67. 
     Though these “conventional” targeted therapies have achieved some clinical success, some new 
concepts have emerged in recent years. Conventional targeted cancer therapy targets the characteristics 
that exclusively exist or are overexpressed in cancer cells. However, little research has been done in the 
opposite direction: targeting characteristics that cancer cells lack/lose. Alterations in the p53-encoding 
gene TP53 are the most common genetic alterations that have been confirmed in 12 of the most common 
cancer types68, either mutated or deleted. Molecules with similar functions have not been found. Several 
other attempts have shown promise for a new strategy in targeted therapy.  
    MDM2 and MDMX proteins inhibit the tumor suppressor gene p53 by blocking its transcriptional 
activity69, and the expression of these proteins is found amplified in many tumors70–72. These findings led 
to the identification of MDM2 and MDMX proteins as targets for cancer treatment. Nutlin-3a is a small 
molecule that can block the binding between p53 and MDM2, through which p53 is stabilized73. Nutlin-3a 
has been found to suppress tumor cell proliferation and promote apoptosis74,75. In addition, it has been 
shown that nutlin-3 can radio-sensitize laryngeal carcinoma cells76. Human trials on derivatives of nutlin-
3a began recently. 
    When a tumor suppressor gene is mutated/deleted, its neighboring genes are often altered at the same 
time. These “passenger” genes are also targets of interest. A recent study was conducted to propose ENO1 
as a new target in treating glioblastomas and possibly other cancers77. As a part of the lp36 locus, where 
several tumor suppressor genes locate78,79, the passenger gene ENO1 is often homozygously deleted in 
glioblastomas. While ENO1 still expresses in normal cells, ENO2, the back-up gene of ENO1 makes the 
cancer cells tolerable. It was hypothesized that if ENO2 is blocked then ENO2 inhibitors can exclusively 
kill the cancer cells77. Furthermore, it has been estimated that among all protein-coding genes in the 
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human genome, 11% are deleted in cancers80. This ENO1-ENO2 model can potentially be applied to other 
cancer types.  
    These “passenger events” are attracting much attention. Other alterations such as the loss of POLR2A 
in colorectal cancer81 and the deletion of PSMC2 in ovarian cancer82, are giving us a better idea in this 
new area of targeted therapy.   
 
1.2.4 Immunotherapy 
Cancer is a result of gene mutations; however, as a part of human body, cancer cells are still, to some 
extent, under the control of the body’s own immune system. That is to say, cancer cells are not completely 
autonomous in their growth. Based on this fact, it is proposed that by stimulating the body’s immune 
system, cancer cells can be more effectively recognized and killed.  
    Back in the 1990s, the role of Interferon g (IFN-g), a pleiotropic cytokine, in promoting host resistance 
to infectious organisms was unequivocally confirmed83,84. In 1998 it was first demonstrated that IFN-g 
played a critical role in cancer immunesurveillance85. In that study the authors found mice lacking IFN-g 
sensitivity were more frequently and rapidly to develop tumors when they were exposed to 
methylcholanthrene, a chemical carcinogen. Then in 2001 Shankaran and coworkers further revealed that 
by collaborating with lymphocytes, IFN-g could restrain the development of sarcomas (carcinogen-
induced) and epithelial carcinomas (spontaneous), as well as reduce immunogenicity86. However, this 
process would also result in the immune-selection of tumor cells that were more adaptable in the immune-
competent environment. Now we understand that the action taken on cancer cells by the immune system 
is a duality: the immune system can suppress tumor growth on one hand, and can promote tumor growth 
on the other hand. This duality is called immunoediting3.  It has been shown that patients who have 
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undergone organ transplantation have a higher risk of developing cancer due to the long-term uptake of 
immune-suppression medication to prevent transplant rejection87.  
    Recall the hallmarks of tumor formation: one of the capabilities is evading immune destruction; without 
this step a tumor cannot be formed5. In an immune-competent host, cancer cells survive and grow, either 
by producing signals that can escape detection/destruction by the immune system or by making changes to 
make them more difficult to be detected. The idea of immunotherapy is to restore and/or to enhance the 
immune system to fight against cancer, either by stimulating activities of specific components of the 
immune system, or by counteracting those “cheating signals” produced by cancer cells. 
    Current immunotherapies can be classified into five main categories: tumor antigen-targeted 
monoclonal antibodies, immunological checkpoint modulators, cell therapy, vaccines, and immune-
modifying agents88. Following is a brief introduction to mAbs infusion and cell therapy.  
    Tumor-specific monoclonal antibodies (mAbs) infusion is a passive immunization. Tumor-specific 
monoclonal mAbs can directly or indirectly activate immune response and result in cell death via different 
mechanisms89. About 25% of breast cancers have been found to overexpress Her290, the human epithelial 
growth factor (EGF) receptor 2. The binding of EGF and the EGF receptor controls a key cellular growth 
regulatory pathway. On the basis of this knowledge, blocking the binding of EGF and EGF receptor and 
/or inhibiting the EGF receptor kinase would possibly inhibit tumor growth.  
    Cell therapy is an active immunization. “Active” means that this therapy uses the natural killers in the 
body, T cells, to fight against cancer cells. It has been shown that intratumoral T cells are crucial in the 
overall survival of various cancers91–93. For example, by measuring the tumor-infiltrating T cells in tumor 
specimens from advanced ovarian carcinoma patients, it was found that the median overall survival (OS) 
of patients with intratumoral T cells is 50.3 months, which is significantly longer than that of patients 
without intratumoral T cells, which is 18.0 months. Moreover, the 5-year OS had a dramatic increase from 
4.5% to 38%91. With this understanding, it was proposed that if immune cell concentration can be 
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increased locally then cancer cells can be killed more effectively. This immunotherapy is called adoptive 
cell transfer (ACT). One form of ACT is called tumor-infiltrating lymphocytes (TILs), in which cytotoxic 
T cells that have invaded a patient’s tumor are harvested outside the human body, and then a large amount 
of these cells are infused back into the patient to kill cancer cells94.  
 
1.2.5 Hormonal Therapy 
Hormonal therapy is also known as endocrine therapy, it is a therapy that targets the signaling pathway of 
the production of hormones, estrogen, for example. Estrogen production starts from the hypothalamus. 
After the signal arrives the pituitary gland, the adrenal glands, estrogen is produced and goes to the breasts. 
Estrogen can control the growth of breast cancer cells95,96. 
    Among all breast cancer patients, 70% to 80% are estrogen-receptor (ER) and/or progesterone-receptor 
(PR) positive97; that is to say, these cancer cells can receive signals from estrogen or progesterone and 
therefore their growth can be promoted. These breast cancer patients are considered hormone responsive. 
Moreover, it has been found that estrogen and progesterone are possibly involved in tumor metastasis98.  
    There are multiple ways to prevent the growth promotion caused by estrogen binding with receptors. 
Drugs are used to decrease the concentration of estrogen in the body. GnRH antagonists such as 
Leuprolide act as agonists at pituitary GnRH receptors, which interfere with the normal pulsatile 
stimulation and finally desensitize GnRH receptors99. Aromatase inhibitors such as Anastrozole interfere 
with the production of estrogen by blocking aromatase that is involved in transferring antigen to 
estrogen100. These two types of inhibitors can effectively reduce the estrogen level in the body, and 
therefore the disease can be controlled101. Another alternative is to directly block the binding of estrogen 
to its receptor on cancer cells. An example is Tamoxifen and it has achieved great success102,103. Dr. 
Daniel Rayson, a medical oncologist, said, “Any degree of estrogen receptor (ER) or progesterone 
receptor (PR) positivity (≥1%) indicates potential hormonally-responsive disease and identifies women 
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who are candidates for Tamoxifen”. Hormonal therapy is also promising in treating other hormone-
sensitive cancers like prostate cancer104.  
 
1.2.6 Other New Cancer Treatments 
Up to now, cancer therapies are applying the “cell-killing” method to treat cancers. Researchers are also 
working on other strategies. A recent study by Dow and coworkers shows that it is possible to convert 
colorectal cancer (CRC) cells to functional normal cells105. It has been shown that the predominant (80%-
90%) CRC-associated event is the disruption of adenomatous polyposis coli (APC), which is a tumor 
suppressor106. Dow’s work shows APC loss plays an important role in the maintenance of CRC. It has 
been found that APC has the capability to re-establish control over crypt homeostasis in mice with 
aggressive polyps/cancer. APC disruption causes polyp development (ON Dox); and by restoring APC, 
the adenoma regresses (OFF Dox) along with the recovery of normal intestinal function. 
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1.3 Chemotherapy 
The term “chemotherapy” was first used in the early 1990s by the German chemist Paul Ehrlich, meaning 
using chemicals to treat diseases. The history of cancer chemotherapy is summarized in the timetable 
shown in Figure 1-3107. Successful systematic cancer chemotherapy was marked by the use of nitrogen 
mustard to treat lymphoma108. At that moment, the time for modern cancer chemotherapy began.  
 
Figure 1-3: History of chemotherapy107. 
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Chemotherapy is aimed to kill cancer cells by cytotoxic agents. Several cellular targets have been 
identified: DNA, DNA regulatory proteins, microtubules, and antimetabolites. Chemotherapeutic drugs 
targeting these cellular parts are introduced as follows. 
1.3.1 Targeting DNA: DNA Cross-linking Agents 
Deoxyribonucleic acid, DNA, which carries the most of the genetic information, is the target for a big 
family of anti-cancer agents. These agents, intended to kill cancer cells, are DNA cross-linking agents. 
DNA cross-linking agents are classified as alkylating agents and platinum complexes (sometimes termed 
semi-alkylating agents).  
Alkylating agents’ cytotoxicity arises from their capability of forming covalent linkage to nucleophilic 
sites (e.g. DNA bases) by their electrophilic/substituted alkyl groups109. As a result, DNA replication and 
transcription could be disrupted. The “cross-linking” takes place through the replacement of a hydrogen 
atom in a DNA molecule (or other molecules) by an alkyl radical in the alkylating agent110.  
An example of alkylating agent is mechlorethamine, which was the first alkylating agent used to treat 
cancer. A simplified schematic graph showing the mechanism of its action is shown in Figure 1-4: 
 
 
As can be seen, these agents possess two reactive groups and therefore they are able to form cross-links 
between molecules. Structurally, alkylating agents can be classified into: nitrogen mustards (aka 
Figure 1-4: Mechanism of mechlorethamine alkylating DNA. 
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bischloroethylamines), nitrosoureas, and others. Alkylating agents are generally considered to have poor 
selectivity due to the fact that they can also alkylate nucleophilic groups on proteins111.  
Platinum complexes, especially Cisplatin, will be introduced in detail in later sections.  
 
1.3.2 Targeting DNA Regulatory Proteins: Topoisomerase Inhibitors 
Several classes of enzymes regulate the action of DNA: DNA polymerases, DNA ligase, RNA primer, 
DNA primase, helicases, single strand binding proteins, topoisomerases, etc. DNA topoisomerases are a 
crucial group of nuclear enzymes involved in a number of DNA metabolic events (replication, 
transcription, recombination, chromosome condensation, and segregation)112 through the alteration of the 
conformation and topology of the DNA during these cellular processes, specifically by causing transient 
DNA breaks on one (type I) or both DNA strands (type II)113–116. Based on these findings, it is expected 
that when the enzyme-mediated DNA breaks fail to reseal, cell death could be induced, and that is how 
topoisomerase inhibitors/poisons execute their anticancer activities117,118.  
 
1.3.3 Targeting Metabolic Processes: Antimetabolites 
Antimetabolites are defined as drugs that interfere with normal cellular metabolic processes119, and they 
belong to an important family of cytotoxic chemotherapeutic drugs. Antimetabolites have similar 
structures as natural cellular molecules used in DNA and RNA synthesis, and they execute their anti-
tumor activity by incorporating themselves into RNA or DNA molecules or blocking the pathways that 
allow a cell to make DNA/RNA and divide120,121. Three categories of antimetabolites are used in cancer 
treatment: pyrimidine antagonists, purine antagonists, and folate antagonists. Attention has been drawn to 
the anti-cancer activity of antimetabolites from Farber’s discovery that aminopterin could cause remission 
of leukemia122.  
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1.3.4 Targeting Microtubules: Microtubule Poisons 
Precisely regulated cell cycle events guarantee the proliferation of eukaryotic cells, and it has been 
noticed that the cell cycle and its check points potentially make valid anti-cancer targets123–125. Functions 
of microtubules maintain cell shape and help cellular movements126. Moreover, the involvement of 
microtubules in chromosomal separation during mitosis suggests the disruption of microtubules would 
induce mitotic arrest and eventually cell death. Tubulins are building blocks of microtubules; microtubule 
poisons are classified into two main groups, based on their binding sites on tubulins and their mechanisms 
of action; they are: taxanes and vinca alkaloids. Taxanes block the disassembly of microtubules and 
thereby induce a G2-M arrest followed by apoptosis, whereas vinca alkaloids block the assembly of 
microtubules. Taxanes such as paclitaxel, docetaxel, albumin-bound paclitaxel, vinca alkaloids such as 
vincristine, vinblastine, and vinorelbine, have all been applied in clinical cancer therapy. 
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1.4 Cisplatin  
Platinum compounds are important cytotoxic drugs in treating cancer, and Cisplatin is the most commonly 
used chemotherapy drug in North America. As mentioned previously, Cisplatin, a platinum complex, is a 
DNA cross-linking agent that possesses anti-cancer activity. In this section, its discovery, success, and 
clinical limitations will be discussed. The chemical structure of Cisplatin is shown in Figure 1-5: 
 
Figure 1-5: Chemical structure of Cisplatin 
 
1.4.1 The Discovery of Cisplatin and Its Clinical Success 
The discovery of Cisplatin was serendipitous and legendary. It was first synthesized in the year of 1844 
by M. Peyrone127, and the structure of which was deduced by Alfred Werner in 1893128. For his work of 
proposing the octahedral configuration of transition metal complexes Alfred Werner won the Nobel Prize 
in Chemistry in 1913. In the 1960s, a biophysicist Barnett Rosenberg and his coworkers put platinum 
electrodes into a solution. When they turned on the power, bacteria in the solution stopped dividing. At 
that time, platinum was considered to have no biological activity; therefore, they thought they had 
discovered a new way to inhibit cell division by electrical current. After two years’ research in this 
direction they found that rather than electrical current it was a compound released from the electrode that 
inhibited the growth of bacteria. Rosenberg’s group spent another two years to identify this 
compound129,130, which is the now well-known Cisplatin.  
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Figure 1-6: History of Cisplatin being an anti-cancer drug. 
Following their previous discoveries, Rosenberg’s team did further research to test if Cisplatin can inhibit 
cancer cell divisions and obtained positive results in mice with sarcoma131.  In the year 1971 Cisplatin was 
first used to treat a cancer patient; the Food and Drug Administration (FDA) approved its clinical use in 
1978.  
    Since being clinically used in treating cancer patients, Cisplatin has achieved great success with a broad 
spectrum of cancers. Across this spectrum, Cisplatin treatment of testicular cancer is phenomenal. The 
treatment of testicular cancer has demarcated the “pre-Cisplatin chemotherapy era” to “the era of 
Cisplatin”132. In the 1950s, the 1-year survival of metastatic testicular cancer patients was as low as 10%; 
now, with the help of Cisplatin, the overall 10-year survival of testicular cancer is 95%133 and the cure 
rate of its metastatic disease is higher than 80%132. Testicular cancer is now the most curable solid tumor.  
    Now, Cisplatin-based treatments are considered as standard treatments for ovarian cancer134, cervical 
cancer135, lung cancer136, head and neck cancer137, bladder cancer138, and lymphoma139. Although new 
therapies are emerging, platinum-based drugs are still being prescribed to 10~20% of all cancer patients, 
according to the NIH (National Cancer Institute).  
1845 1893 1960s 1978 
Cispla'n	ﬁrst	
synthesized	
Structure	
deduced	by	
Alfred	Werner	
Rosenberg	
discovered	its	
an'-cancer	
ac'vity	
1971 
First	'me	
cispla'n	
applied	to	a	
cancer	
pa'ent	
Became	available	
for	clinical	
prac'ce	as	
Pla'nol	
	
  20 
1.4.2 Limitations of Cisplatin 
Although Cisplatin is such a potent anti-cancer drug, its severe toxicity and the development of resistance 
to Cisplatin often limit its clinical application. In this section different forms of Cisplatin-related toxicities 
and intrinsic/acquired resistance of Cisplatin will be introduced in detail.  
 
1.4.2.1 Cisplatin Related Toxicity 
Cisplatin-related toxicities are dose-dependent, and they occur mostly on organs, including the kidneys, 
the nervous system, and the organ of Corti140. In this section, several forms of Cisplatin-induced toxicities, 
especially nephrotoxicity and neurotoxicity, and clinical measures to ameliorate these toxicities will be 
introduced.  
 
1.4.2.1.1 Nephrotoxicity  
It has been known for years that heavy metals cause human nephrotoxicity, such as renal failure with 
tubular injury and chronic dysfunctions141. Nephrotoxicity is the most common and the most clinically 
significant side effect associated with the administration of Cisplatin142, and it has been the major dose-
limiting toxicity143,144; high-dose Cisplatin treatment induces severe renal dysfunction in ~20% of 
patients145.  
Nephrotoxicity induced by Cisplatin presents in various forms, and these renal manifestations have 
been summarized by Ronald Miller146, which are shown in table 1-1: 
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Table 1-1: Cisplatin-induced renal manifestations. 
 
Among these types of nephrotoxicity, acute kidney injury (AKI) is the most serious as well as a very 
common form. 
    Several factors account for Cisplatin-induced nephrotoxicity. First, from the perspective of 
pharmacology, the kidneys are the major organs for the excretion of Cisplatin. Studies in rats suggest that 
after 24 hours of Cisplatin injection, 50% of Cisplatin is excreted through urine; most platinum shows up 
in the first hour after treatment. It has been estimated that the concentration of Cisplatin in proximal 
tubular epithelial cells is about 5 times higher than that in the plasma147. Second, it has been demonstrated 
that Cisplatin molecules undergo metabolic activation to become more toxic in the kidney148,149. 
Unfortunately but inevitably, other reasons for nephrotoxicity (renal cell death) are related to the 
cytotoxicity of Cisplatin (which will be discussed in later sections). Pathways involved in nephrotoxicity 
also contribute to Cisplatin’s anti-tumor activity. That is to say, methods that are used to reduce Cisplatin-
induced kidney dysfunction may also reduce its anti-cancer effectiveness. 
    Supportive measures have been developed to ameliorate nephrotoxicity caused by Cisplatin. NaCl 
hydration prevents Cisplatin ligand exchange and subsequent platinum-protein damage150; at the same 
time, it shortens the time that Cisplatin molecules are in contact with renal tubules151. The current standard 
method is to combine adequate hydration before, during, and after Cisplatin administration with osmotic 
Cispla'n	Treatment	Induced	Renal	Manifesta'ons		
Acute	Kidney	Injury	(20-30%)	 Hypomagnesemia	(40-100%)	
Fanconi-like	Syndrome	 Distal	Renal	Tubular	Acidosis	
Hypocalcemia	 Renal	Salt	WasHng	
Renal	ConcentraHng	Defect	 Hyperuricemia	
Transient	Proteinuria	 ErythropoieHn	Deﬁciency	
ThromboHc	Microangiopathy	 Chronic	Renal	Failure	
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diuretics such as mannitol or furosemide; this method has been proved effective in mitigating the side 
effects of platinum compounds152–154. It has also been found that the prolongation of Cisplatin infusion (> 
6 hrs) can reduce Cisplatin-induced renal insufficiency155. Besides, how drugs are given also matters; dose 
fractionation156,157 and chronomodulated schedule158 have also been proposed to lower the incidence of 
kidney damage and organ toxicity. In addition, different kinds of agents have been found to have the 
potential to ameliorate nephrotoxicity. These include antioxidant/antilipid peroxidation agents159–162 and 
nitric oxide modulators & adenosine159,163. 
 
1.4.2.1.2 Neurotoxicity 
According to the “Overview of neurologic complications of platinum-based chemotherapy” from 2016 
UpToDate®, Cisplatin-induced peripheral neuropathy is summarized in Table 1-2: 
 
Table 1-2: Cisplatin-induced peripheral neuropathy. 
 
The incidence of peripheral neuropathy is largely related to the cumulative dose of Cisplatin. 
Neuropathy starts to develop when the cumulative dose reaches 300 mg/m2; and almost all patients will 
experience neuropathy when the cumulative dose exceeds 500 mg/m2 164,165. More treatments may 
aggravate neuropathy and result in “generalized loss of deep tendon reflexes and more proximal vibratory 
sensory impairment”164. Moreover, time-course studies have suggested that only 11% of patients 
Cispla'n	Treatment	Induced	Peripheral	Neuropathy	
Sensory	 Motor	 Reﬂexes	 Autonomic	 Recovery	
Distal,	symmetric	loss	of	
sensa9on	to	all	
modali9es,	stocking	
glove	distribu9on;	
painful	paresthesias	or	
numbness	
Normal	 In	
propor9on	
to	sensory	
loss	
Rare	 Par9al;	may	progress	for	
several	months	aDer	
drug	is	discon9nued	
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experience neurotoxicity right after the completion of Cisplatin treatment, while the proportion goes up to 
65% after an additional 3 months of treatment140. 
Generally speaking, platinum-based drugs affect the axons, myelin sheath, neuronal cell body, and the 
glial structures of the neurons166. At the cellular level, these drugs damage DNA by interfering with DNA 
replication and metabolism in the neurons167, just as they do to the cancer cells. From the perspective of 
the whole system, platinum compounds cannot readily penetrate the blood-brain barrier. However, they 
can easily enter the dorsal root ganglia and peripheral nerves; that explains the finding that the dorsal root 
is the primary site of neurotoxicity168. Besides, oxidative stress and mitochondrial dysfunction have also 
been proposed as the reasons for neuronal apoptosis169–171.  
Some measures used to reduce platinum nephrotoxicity have been effective, such as dose fractionation 
and the prolongation of infusion172. In addition, neuro-protectants agents have been tested156,164.  
 
1.4.2.1.3 Ototoxicity 
Ototoxicity, presented as tinnitus and bilateral high-frequency hearing loss, occurs in 75-100% of patients 
treated with Cisplatin, it is cumulative and possibly irreversible173. The formation of highly reactive 
oxygen radicals and the depletion of glutathione have been suggested to be responsible for Cisplatin-
induced damage to the outer hairy cells of the cochlea174. Amifostine that has been used to reduce 
neurotoxicity is applied as a tissue protectant, and it has been also proved effective in reducing Cisplatin-
induced ototoxicity175.  
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1.4.2.1.4 Other forms of Cisplatin-related toxicities  
Other forms of Cisplatin-induced side effects are also observed. Nausea and vomiting are common in 
patients receiving Cisplatin treatment, which can be ameliorated by adjusting the time of drug 
administration and the application of antiemetic agents like aprepitant140.  Cardiovascular toxicity has also 
been observed short after Cisplatin infusion140.  
    Overall, the most severe toxicity of Cisplatin is mainly due to the binding of the heavy-metal platinum 
(Pt) to proteins in kidneys176,177. The problem is so severe that it even prompted the call to discontinue the 
clinical use of Pt-based anticancer drugs178.  
 
1.4.2.2 Intrinsic and Acquired Resistance of Cisplatin 
In Cisplatin-based cancer therapy, drug resistance is another problem. Resistance is the most important 
limitation for the effectiveness of cancer chemotherapy, and it accounts for more than 90% of treatment 
failure in patients with metastatic diseases179. Two forms of chemotherapy resistance are: intrinsic and 
acquired. In this section, both forms of resistance to Cisplatin will be discussed. 
    Intrinsic resistance means that before receiving the treatment, there are “resistance-mediating factors 
pre-exist in the bulk of tumor cells that make the therapy ineffective”180. Non-small-cell lung cancer, 
which accounts for 80-85% of lung cancer cases181, is an example of cancer that is intrinsically resistant to 
Cisplatin treatment. The response rate is normally lower than 20%182.  
    Acquired resistance develops during treatment which is effective initially. Compared to intrinsic 
resistance, acquired resistance is more complex. Causes can be mutations, cellular adaptive responses, and 
the activation of alternative compensatory signaling pathways179. One example of acquired resistance to 
Cisplatin is ovarian cancer. Patients generally have a good initial response rate of ~70% while the 5-year 
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survival rate is only 15-20%; of which the primary reason is drug resistance183. Another example is the 
small-cell lung cancer, with a  reported relapse rate of ~95%184.  
Chemotherapy resistance is a self-protective strategy for tumor cells. Studies on cellular/molecular 
mechanisms for Cisplatin resistance are of great clinical importance. From the exposure to Cisplatin to the 
final cell death (apoptosis), each step provides a chance for a cell to fight and survive and hence to 
develop drug resistance. Chemotherapy resistance, not limited to that against Cisplatin, takes place at 
different levels which are summarized in Figure 1-7179: 
 
Figure 1-7: Big picture of chemotherapy resistance mechanisms. 
 
It has been suggested by Dr. Lorenzo Galluzzi and coworkers that mechanisms accounting for Cisplatin 
resistance are studied based on when they occur: pre-target, on-target, post-target, and off-target185. (1) 
Pre-target resistance involves two major mechanisms: reduced intra-cellular accumulation of Cisplatin, 
and increased consumption of Cisplatin by scavengers like Glutathione (GSH, γ-glutamyl-cysteinyl-
glycine), metallothioneins, or other nucleophilic species in the cell. Non-small-cell lung cancer, which is 
intrinsically resistant to Cisplatin, has a significantly higher level of GSH than that in normal lung 
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tissues186. (2) On-target resistance involves the recognition of Cisplatin-induced DNA adducts as well as 
the final apoptotic signal, and the DNA repair process. It has been found that in cancer cells that are 
resistant to Cisplatin, cellular damage recognition is often poor. The NER (nucleotide excision repair) 
system is responsible for the repair of DNA adducts, the major lesions caused by Cisplatin187. An 
important group of proteins participate in NER is ERCC1; it has been found that ERCC1 expression is 
inversely correlated with the effectiveness of Cisplatin-based treatment in several cancers, including non-
small-cell lung188, colorectal189,  and ovarian cancers190. (3) Post-target resistance presents as the 
interference with apoptosis pathways, and it can be achieved by genetic/epigenetic alterations. In 
approximately half of cancers, TP53 is inactivated191. As we have discussed in the previous section, 
testicular cancer is very sensitive to Cisplatin-based treatment. It has been shown that in testicular germ 
tumor cells, TP53 is almost never inactivated192. In addition, ovarian cancer patients with TP53 mutations 
have a lower chance of taking advantage from Cisplatin-based treatment, compared to those do not have 
TP53 mutations193. (4) Off-target resistance caused by signaling pathway changes that are not directly 
related to the exposure of Cisplatin. These changes may interfere with apoptosis signals induced by 
Cisplatin. HER-2 over-expression194,195, autophagy196,197, and the heat-shock response198,199 have been 
shown to contribute to Cisplatin resistance.  
Understanding the mechanisms of chemotherapy resistance to Cisplatin and other anti-cancer drugs 
helps to design more effective treatment.  
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1.5 Chemotherapy and Combination Chemotherapy 
1.5.1 Why Combination Chemotherapy 
The history of using drugs to treat cancers goes back at least 500 years. However, successful systematic 
cancer chemotherapy was actually developed in the 1940’s, marked by the first clinical trial of nitrogen 
mustard in patients with lymphosarcoma, conducted by Gilman, Goodman, Lindskog, and Dougherty in 
1942108. The first cured cancer by chemotherapy was reported in 1961 when women with gestational 
choriocarcinoma were cured by one of the antimetabolites, methotrexate200. Since then, various classes of 
anti-cancer agents have been developed, including alkylating agents targeting the DNA, antimetabolites 
targeting the DNA synthetic pathways, topoisomerase inhibitors targeting DNA regulatory proteins, and 
mitotic spindle poisons targeting microtubules201, as discussed in the previous section.  
    There are two issues when single anti-cancer agents are used to treat cancer. First, currently there is no 
anti-cancer drug with a “perfect” selectivity. The use of these cytotoxic agents would induce toxicity more 
or less to normal tissues. Taking Cisplatin as an example, to get satisfactory/curing effect, the required 
dose is often high enough to induce severe nephrotoxicity, neurotoxicity, ototoxicity, etc140,156,173. Second, 
though many anti-cancer drugs have been shown effective, “even the most successful targeted therapies 
lose potency with time”202. Both intrinsic203 and acquired204 drug resistance are limiting the long-term 
efficacy of a single drug. Because of these two issues, clinical response from a single agent is limited. 
    Combination therapy was proposed to overcome these two limitations. By using two or more drugs 
together to treat cancer, the individual dose of each drug can be reduced and therefore the individual 
toxicity from each drug is expected to be limited (when they have different forms of toxicity). Meanwhile 
if multiple drugs are combined, the probability of selecting tumor cells that are resistant to all of these 
drugs will be lower, given they have different biochemical mechanisms of resistance205. Overcoming the 
drug resistance was “the most important factor that prompted studies of the effects of drug combination in 
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cancer treatment”206. Additionally, by combining multiple drugs that target different components of a cell 
and/or different cell cycles, the cell-killing efficacy may be enhanced. A classic example of the value of 
combination chemotherapy is the treatment of acute lymphocytic leukemia (ALL) in childhood. Before 
the development of the drug 6-Mercaptopurine (6-MP), the average survival for children with ALL was 
3~4 months. With 6-MP’s single-agent chemotherapy, remissions were induced207; however, subsequent 
courses of this mono-therapy became progressively less effective, yielding a median survival of 6 months. 
By using the regimen combining vinblastine, prednisone, and methotrexate with 6-MP, a > 95% of 
complete response (CR) was achieved and 10% of patients were cured; and other combinations of more 
drugs (7 or 10 drugs) gave > 95% of CR and 75-80% of cure rate208,209.  
    As we can see, combination chemotherapy does give a hope to cure cancer, and different combinations 
give different responses. 
 
1.5.2 Synergy Evaluation 
Currently, almost all anti-cancer drugs are given in combinations; the clinical use of a combination for a 
specific type of cancer needs the approval from the FDA. There is a long way from bench to bedside; 
therefore, in order to give a better prediction on the clinical success of a combination, it is important to 
build accurate and robust evaluation systems for preclinical trials. 
 
1.5.2.1 Building Good Models 
To test the anti-cancer efficacy of drugs, preclinical trials include in vitro assays on cell cultures and in 
vivo animal experiments. When multiple drugs are used in combination, three possible interactions 
between/among drugs are: synergistic (“working together”), antagonistic (“working against each other”), 
or simply “additive” (or “expected”). Preclinical trials give us survival curves of cultures, dosages of 
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drugs, effective sequencings of drug administration, etc. In order to predict the clinical value from these 
data, a model has to be built to assess the interaction. The model should be simple but robust, and should 
take each drug’s pharmacokinetic profiles into account210.  
    Dr. Patrick Reyholds suggested five principles for in vitro digital image microscopy-based cytotoxicity 
assay (DIMSCAN) to test drug combinations; these can also be transferred to other in vitro tests211: 
(a) Cell survival should cover a wide range, and the “two-log” rule should be followed212. 
(b) More than one cell line should be tested (both drug-sensitive and drug-resistant cell lines). 
(c) The mechanism of each drug’s resistance should be identified. 
(d) The dosage and schedule should be achievable in the clinic. 
(e) Effects under hypoxic conditions should be investigated. 
    In addition, other aspects like the growth conditions (human plasma) should be also taken into account.  
    After building good models and obtaining concentration-effect curves, whether or not synergy exists 
between two/multiple drugs is ready to be assessed. When researchers get the raw data, the most 
important task is to extract biological significance from the statistical significance, which remains 
challenging, although a number of sophisticated methods have been developed213. Different evaluation 
methods will be introduced in this next section. 
 
1.5.2.2 Synergy Evaluation Methods 
1.5.2.2.1 Fractional effect analysis 
The first synergism analysis method, which was proposed by Webb in 1963, is known as the fractional 
effect analysis, and remains the simplest and the most straightforward method214. Based on this method, 
when the observed effect is greater than the product of the effects of each individual agent, the 
combination will be considered synergistic. Survival from the calculated product of the effects of each 
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agent is called the “additive” or “expected” survival. By comparing the observed and the expected curves, 
synergy can be concluded when the observed survival is lower than that of the expected.  
    The fractional effect method is the most straightforward. Based on this analysis the “additive” effect of 
two drugs is assumed be the product of the fractional activities: 
 (𝑓+)-,/ = (𝑓+)-×(𝑓+)/ 
    In the above formula, (f3)-,/  represents the expected fraction of the system unaffected by the 
combination treatment of drug 1 and 2. (f3)- and (f3)/ represent the fractions of the system unaffected by 
the treatment of drug 1, and drug 2, respectively. 
    This expression agrees with the nonexclusive first-order behavior. It means the fractional product 
method cannot be used for cases where drugs are mutually exclusive. As a result, if two drugs with similar 
mechanisms of action are used in combination, their interaction cannot be analyzed using this method. In 
addition, by using this method it is assumed that the concentration-effect relationship is hyperbolic. 
However, different drugs exhibit different survivals (sigmoidal or flat sigmoidal curves), so this method 
does not apply to all cases. Moreover, only a mathematical expression is considered in this model, no 
biology is taken into account. Furthermore, only when the dose-effect relationships of the two drugs 
follow Michaelis-Menten-type hyperbola (m=1) can the fractional product method be used.  
    Though the application of the fractional effect method is highly restricted, it is still frequently used due 
to its simplicity215. This fractional effect analysis will be used in this thesis for the evaluation of synergy.  
 
1.5.2.2.2 Other synergy evaluation methods 
    Another synergism analysis method is to plot isobolograms of the effects from using single/combined 
drugs, which has been taken as the gold standard in the assessment of synergism216,217. From in vitro cell 
survival experiments of single agents A and B, a straight line connecting their equally effective (e.g. 50% 
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of the untreated, IC50) doses gives the additive isobole for that specified effect (killing 50%). Through 
survival experiments testing the combination of A and B, “pairs” of concentrations that give the same 
cell-killing/survival (IC50) can be determined. These “pairs” are used to plot the “iso-effect” curve. If the 
plotted curve is lower than the additive isobole, the tested combination is considered as synergistic; if the 
curve is higher than the isobole, the combination is considered as antagonistic.  
    Based on the isobologram method, Berenbaum introduced the “interaction index” in 1989217 to 
numerically indicate if a combination is synergistic or antagonistic. This index can be used for not only 
two-drug combinations, but also multiple-drug systems. The “additive curves” are defined by: 𝑑5𝐷5 = 1	 𝑖 = 1, 2, … , 𝑛<5=-  
    When the sum of observed effects of a given combination is smaller than 1, the combination is 
considered as synergistic; when the observed value is greater than 1, the combination is considered as 
antagonistic. The response surface approach was introduced based on the isobologram method218. 
However, it is not frequently used due to its mathematical complexity.  
    Chou and Talalay developed the median-drug effect method in 1984219, and this method has been 
applied to assess potential synergism among different drugs. This method takes the drug combination as a 
“single” and a “new” drug. Therefore, to test the concentration-survival curve of this new drug, the ratio 
of individual drugs should be fixed; that is to say, the relative effect of each drug in this ensemble is fixed. 
The mathematics of this method will not be introduced due to its complexity.  
    Combination therapy has achieved some success in cancer treatment when components in a 
combination have a favorable pharmacological interaction (same target, but different large-organ 
toxicities), as commented by Dr. Edward Sausville. However, the development of a drug combination is 
not an easy task, in the sense of the time and effort put before it could be clinically applied. Making the 
best out of preclinical models and overcoming intrinsic and extrinsic barriers of combination therapy are 
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the next step after we get a “good idea”. Very often successful preclinical studies fail in clinical trials220. 
Poor concordance between preclinical and clinical results comes from: when molecular heterogeneity 
cannot be fully reflected by limited cell line models; when optimal dosing and sequencing of agents 
cannot be determined by limited attempts; and when the sensitivity or resistance cannot be completely 
determined by limited attempts221. Despite all the efforts made on developing these methods, none is 
perfect. Future work should not only rely on models, but also on more precise understandings of 
biological interactions between/among drugs.  
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1.6 Combination Chemotherapy of Cisplatin: A Literature Review 
Cisplatin is a potent anti-cancer drug and one of the few curative agents of treating cancer. Current cancer 
chemotherapy often combines two or more drugs together to increase the therapeutic effect, to reduce 
chemo-resistance, and to limit the toxicity induced by each agent in the combination. To treat a certain 
kind of cancer, pre-clinical combination design first takes drugs that have been shown active in treating 
this cancer into consideration; in order to reduce toxicity and to circumvent cross-resistance, drugs 
targeting different mechanisms and cell cycles are frequently studied. Though combinations are designed 
rationally and some of them have been proved effective in the clinic, precise mechanisms are not always 
clear and therefore it is not easy to predict the efficacy of a designed combination regimen without being 
clinically confirmed. This section reviews pre-clinical and clinical studies investigating the effectiveness 
of Cisplatin combined with topoisomerases, antimetabolites, microtubule poisons, and antibodies.  
 
1.6.1 Cisplatin Is Often Used in Combination 
Being introduced into clinical practice in 1971 after preclinical trials222, Cisplatin has achieved great 
success in treating a broad spectrum of cancers. Despite being such a potent and one of the few curative 
anticancer drugs, its clinical application is often restricted by its side effects140 and drug resistance185. This 
inspires the discovery of other platinum-based agents223. Along with more clinical data and better 
understanding of Cisplatin, the expectation has evolved from “a less toxic but equally efficacious 
analogue”, to a compound “possessing sufficient oral bioavailability”, and finally to one “capable of 
circumventing Cisplatin resistance”224, which gives birth to the second generation of platinum drug 
carboplatin that has a lower overall toxicity 225,226, and the third generation of that oxaliplatin that does not 
have cross-resistance with Cisplatin or carboplatin 227,228. Moreover, supportive clinical measures and 
some protective agents, on the other hand, are proposed and applied to reduce Cisplatin-induced side 
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effects140,229–233. Though extensive studies have been carried out, the resistance of Cisplatin remains the 
major limitation in its clinical use. As a single agent, Cisplatin therapy normally gives an excellent initial 
response rate; however, there is a high rate of tumor recurrence in some cancers because of acquired 
resistance184,234. Combining two or more drugs is now the standard clinical cancer treatment. Attacking 
different targets or interfering with different parts of the cell cycle to achieve synergy, reducing drug 
resistance, and decreasing drug toxicity from each drug are all reasons for using multiple drugs to treat 
cancer and for designing drug combinations. 
    Here the combinations of Cisplatin and topoisomerases, antimetabolites, microtubule poisons, and 
antibodies are individually introduced. 
 
1.6.2 Cisplatin in Combination with drugs targeting DNA-regulatory proteins 
Chemotherapeutic agents targeting DNA regulatory proteins have been introduced in the previous section; 
and Cisplatin is often combined with these agents. 
    Irinotecan, as a semisynthetic camptothecin derivative, is a type I topoisomerase inhibitor that stabilizes 
topoisomerase I –DNA cleavable complexes235–237. Based on their different mechanisms of action238, 
relatively different toxicity profiles140,239, and lack of cross-resistance240,241, Cisplatin and irinotecan have 
been used in combination to treat cancer.  
    Lung cancer is the leading cause of cancer death242. Cisplatin and irinotecan, both of them have been 
proved effective in treating lung cancer243. The combination of these two agents has also been confirmed 
synergistic both pre-clinically244,240 and clinically245. Etoposide, a type II topoisomerase inhibitor, 
combined with Cisplatin (PE), used to be the standard treatment for small-cell lung cancer (SCLC); the 
response rate of which ranges from 60% to 90% and the median survival ranges from 8 to 11 months246–248. 
Compared with PE, the PI regimen is proved more effective shown in medium survival (12.8 months vs. 
9.4 months), one-year survival (58.4% vs. 37.7%) and two-year survival (19.5% vs. 5.2%)249. The PI 
  35 
combination regimen has also been assessed in elderly patients with extensive-disease SCLC and this 
regimen has been also confirmed effective250. A triplet combination regimen including Cisplatin, 
irinotecan, and etoposide (PIE) has been studied on extensive SCLC251, the medium survival is increased 
to 15.1 months, suggesting that the PIE regimen is a more efficacious combination. Another triplet by 
adding another topoisomerase-I inhibitor, topotecan, to the standard PE regimen, has also been 
investigated but is shown not beneficial in enhancing response or survival in extended stage SCLC 
patients252. Furthermore, as a type of cancer that is sensitive to both chemotherapy and radiation therapy, 
limited-disease SCLC has been shown to be more responsive to the PI regimen combined with 
radiotherapy253. The PI regimen has also been tested and appears to be acceptable for the treatment for 
advanced thymic carcinoma, for which the optimal chemotherapeutic regimen is still being investigated254.  
    Other combinations of topoisomerase inhibitors and Cisplatin, such as belotecan combined with 
Cisplatin to treat extensive stage SCLC255, have also given promising results.  
 
1.6.3 Cisplatin in Combination with Antimetabolites 
Antimetabolites have been introduced in the previous section. The combination chemotherapy of Cisplatin 
and antimetabolites is a common regimen.  
    5-Fluorouracil (5-FU), as an analogue of uracil with a fluorine atom instead of hydrogen at the C-5 
position, is first metabolized to its active forms (FdUMP, FdUTP, and FUTP), and these active 
metabolites could disrupt DNA/RNA synthesis and inhibit the action of thymidylate synthase that is a 
nucleotide synthetic enzyme256. The combination of 5-FU with Cisplatin has been extensively studied. 
Synergy is observed pre-clinically when Cisplatin is administered before 5-FU, as the first antimetabolite 
combined with Cisplatin257–261. Reasons for 5-FU potentiating the cytotoxicity of Cisplatin are attributed 
to the modulated repair of platinum-DNA adducts257, increased levels of intracellular reduced folates258,259, 
and increased DNA fragmentation260. It has been also shown that the ERCC1 gene encodes a protein 
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participating in the excision step in nucleotide excision repair (NER), through which the amount of 
platinated DNA could be increased262. Moreover, it has been found that if 5-FU exposure is given after 
Cisplatin, the increased gene expression responsible for the two drugs’ resistances can be repressed; 
therefore, synergistic cytotoxicity is achieved263.  
    Penis cancer is a rare cancer264. The response rate of penis cancer to Cisplatin is only 23%265–267, and 
that of the PI combination regimen is reported to be 30.8%268. By combining Cisplatin and 5-FU (PF) to 
treat advanced squamous carcinoma of the penis, the average response rate is increased to 63%269–271, 
which makes the PF regimen the standard treatment for penis cancer. This combination regimen is also 
used to treat advanced head and neck cancer: a 40% 9 months’ survival is achieved by using the 
combination, compared to 24% of that by Cisplatin alone and 27% by 5-FU alone272.  Moreover, the PF 
regimen has also been proved fairly active in treating SCCHN. Hypopharynx cancer, for example, has 
been treated with the PF regimen followed by radiation and this phase III trial has proved that this 
treatment could make larynx preservation feasible273. The PF regimen is also used to treat oropharyngeal 
cancer as a neoadjuvant chemotherapy followed by loco-regional treatment (radiotherapy and/or surgery), 
compared with loco-regional treatment alone. The overall survival is significantly prolonged from 3.3 
years in the loco-regional treatment group to 5.1 years in the group with neoadjuvant chemotherapy274.  
    Gemcitabine, a nucleoside analogue, has anti-tumor effect on various solid tumors275,276 by 
incorporating itself into cellular DNA277–279. Synergy between Cisplatin and gemcitabine was first found 
on cell lines280,281, and the mechanism was attributed to the effects of gemcitabine on intracellular 
Cisplatin pharmacokinetics281. Biliary tract cancer, being an uncommon cancer, often presents as an 
advanced disease when diagnosed. Though some agents have proved active, including Cisplatin282, 
gemcitabine283, and fluoropyrimidines284,285, there is no consensus on the standard regimen for treating 
patients with locally advanced or metastatic biliary tract cancer,. A randomized phase II study was 
initially conducted to evaluate the combination regimen of Cisplatin with gemcitabine, because the 
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progression-free survival was prolonged this study was extended to a phase III study286. According to this 
study, the median overall survival is prolonged to 11.7 months by using Cisplatin combined with 
gemcitabine, compared to 8.1 months by using gemcitabine only, the progression-free survival is 
improved to 8.0 months from 5.0 months, and the tumor control rate is also increased from 71.8% to 
81.4%; these results make the Cisplatin and gemcitabine combination regimen an option for treating 
patients with advanced biliary cancer. 
    A phase III study of the treatment of NSCLC comparing Cisplatin and gemcitabine with Cisplatin and 
pemetrexed has been conducted, showing that the overall survival of these two regimens are comparable 
(10.3 vs. 10.3 months). The Cisplatin and pemetrexed regimen works better in patients with 
adenocarcinoma and large-cell carcinoma histology (12.6 compared to 10.9 months) while the Cisplatin 
and gemcitabine regimen works better in patients with squamous cell histology (10.8 compared to 9.4 
months)287.  
 
1.6.4 Cisplatin in Combination with Microtubule Poisons 
Based on the different anti-cancer mechanisms of microtubule poisons and Cisplatin, they have been 
combined with the hope to achieve clinical synergy.  
    Ovarian cancer is the eighth most common cancer in women242. Due to its seldom early diagnosis it 
often progresses to advanced stage when diagnosed288 and is the most lethal gynaecological cancer289. 
Chemotherapy is the first-line treatment after surgical cytoreduction for ovarian cancer. After Cisplatin’s 
failure as a single-agent in treating ovarian cancer due to resistance, paclitaxel (Taxol) gained clinical 
attention as a single anti-cancer agent290–292 by achieving an overall response rate of 37% in platinum-
treated patients293. Further success was achieved by combining Cisplatin and paclitaxel to treat stage III 
and stage IV ovarian cancer, the response rate of which was 73%, and the median survival was 14 months 
longer than that of the previous combination of Cisplatin and cyclophosphamide (38 vs. 24 months)294. 
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Besides ovarian cancer, the Cisplatin-paclitaxel combination has become the first-line chemotherapy for 
several other types of cancer, including advanced non-small-cell lung cancer295, advanced gastric 
cancer296, advanced breast cancer297, and metastatic esophageal cancer298.  
    Docetaxel, another kind of taxanes, is also applied in combination with Cisplatin to treat advanced 
ovarian cancer299 and gastric carcinoma300. 
    The triplet combination of Cisplatin, docetaxel, and 5-FU (TPF) used as induction chemotherapy has 
also been investigated. The activity of the PF regimen in SCCHN has been discussed earlier and the 
taxanes have also been confirmed effective in treating SCCHN as single agents. Therefore Cisplatin 
combined with 5-FU and docetaxel might be a possible combination for SCCHN and this triplet regimen 
has been proved effective in clinical trials301,302. 
 
1.6.5 Cisplatin combined with antibodies (targeted therapy) 
Cetuximab is a chimeric monoclonal antibody (mouse/human) directed against the extracellular domain of 
the epidermal growth factor receptor (EGFR) that is overexpressed in one third of human cancers and has 
been shown to be related to tumor growth and progression. Due to its capability of binding to EGFR and 
disrupting its function, the antibody is proposed to possess anti-cancer activity303. Early clinical studies of 
cetuximab have been well reviewed304.  
    Squamous cell carcinoma of the head and neck (SCCHN), a collective type of cancer that originated 
from the skin, nasal cavity, paranasal, sinuses, oral cavity, salivary glands, pharynx, and larynx, of which 
90% are squamous cell carcinoma of the mucosal surfaces of the head and neck305. The expression of 
EGFR is almost invariably expressed in SCCHN and the overexpression of EGFR is often related to poor 
prognosis306. Therefore, cetuximab could be a candidate to treat SCCHN. Experiments on cell lines and 
xenografts have both confirmed the activity of cetuximab307,308. Moreover, it has been shown that 
Cisplatin’s efficacy is enhanced by cetuximab309 without affecting its pharmacokinetic profile310. Based 
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on these findings, the combination of Cisplatin and cetuximab is thought to have a better therapeutic 
effect on SCCHN. A phase IB clinical study of Cisplatin and cetuximab combination regimen has been 
conducted on patients who were pre-treated with Cisplatin and who showed resistance to Cisplatin 
therapy, and the result has shown this regimen effective311. A randomized phase III study in patients with 
metastatic and/or recurrent head and neck cancer has been conducted to investigate the efficacy of the 
combination of Cisplatin and cetuximab. The result shows that patients receive weekly cetuximab plus a 
Cisplatin-cetuximab combination every 4 weeks have an objective response rate of 26% and a median 
survival of 9.2 months, compared to 10% and 8.0 months of that by Cisplatin mono-therapy312. 
Additionally, the Cisplatin and cetuximab combination regimen has also been suggested as a possible 
second-line treatment after progression on platinum-based chemotherapy. A phase II study of the 
combination chemotherapy of Cisplatin and cetuximab in patients with recurrent and/or metastatic 
SCCHN has been conducted to confirm the efficacy of this regimen313. A response rate of 10% and a 
median survival of 183 days are achieved, compared to 2.6% and 103 days in patients with advanced 
SCCHN progressed on platinum-based treatment314.  
    Recent clinical studies have tried to combine cetuximab, Cisplatin, and another anti-cancer agent to 
enhance the chemotherapeutic effect. A phase III clinical study shows that the response rate is increased 
from 20% (Cisplatin and 5-FU) to 36% (Cisplatin with 5-FU and cetuximab), the progression-free 
survival is increased from 3.3 months to 5.6 months, and the overall survival is prolonged from 7.4 
months to 10.1 months315, making Cisplatin with 5-FU and cetuximab the standard systemic treatment for 
R/M (recurrent or metastatic) SCCHN. Furthermore, pemetrexed as a folic acid inhibitor has also been 
tried in combination with Cisplatin and cetuximab, but no improvement is achieved compared with the 
standard treatment, and on the other hand this regimen is shown to have a higher treatment-related death 
rate (7.6%)316. 
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1.6.6 Discussion of Cisplatin-Based Combination Chemotherapy  
In spite of the better and deeper understanding of the nature and causes of cancer, and various therapies to 
treat cancer, chemotherapy remains a required treatment in many situations. Cisplatin, as an “old” but one 
of the most widely prescribed anticancer drugs, is still of great clinical importance. As one of the most 
effective chemotherapeutic drugs used in the clinic, Cisplatin is often used in combination with 
topoisomerase inhibitors, antimetabolites, microtubule poisons, and antibodies. In order to design rational 
combinations, synergy is attempted by targeting different cellular mechanisms, interfering with different 
parts of the cell cycle, and using drugs with confirmed activity in treating certain types of cancer. Also, 
relatively distinct toxicity profiles and not being cross-resistant should be considered.  
    Some proposed rules/principles have been helpful in investigating combinations to treat cancer. 
Cisplatin as an alkylating-like agent acts similarly with the alkylating agent cyclophosphamide. Therefore, 
the combination of Cisplatin and paclitaxel, which act more distinctly, should be more effective. These 
two combinations of Cisplatin with cyclophosphamide and Cisplatin with paclitaxel have been compared 
to treat stage III and stage IV ovarian cancer. The results have shown the latter combination is superior in 
terms of both response rate (73% vs. 60%) and median survival (38 months vs. 24 months)294.  
    Though Cisplatin-based combination chemotherapy has achieved some success in the clinic, issues 
remain for further investigation. First, from the perspective of combination design, macroscopic guidance 
does not always guarantee clinical success. For example, the triplet combination including Cisplatin, 
etoposide, and irinotecan significantly enhances the therapeutic effect, whereas a similar triplet 
combination including topotecan plus the PE (Cisplatin and etoposide) regimen does not251,252. Drugs are 
normally combined because both/all of them are active in treating a certain kind of cancer and therefore it 
is anticipated that the combined effect will be enhanced. But this is not always confirmed by clinical 
trials. Second, most of these combinations are dependent on the types of cancer, drug sequence, and the 
population selected for study. For example, the combination of paclitaxel and Cisplatin shows synergy in 
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treating ovarian cancer whereas not in treating SCLC317. The same combination regimen, administered in 
different sequences, sometimes gives opposite conclusions. Clinical trials comparing the effectiveness of 
PE and PI regimens in treating SCLC by the Japanese Cooperative Oncology Group (JCOG) and by 
Nasser Hanna et al. give different answers249,318. Contradictory results could be explained by the 
difference between Asian and Western populations. Moreover, recent studies have confirmed that no 
superiority is observed in extensive-stage SCLC patients treated with PI compared with PE in Western 
patients319,320. In addition, it has also been demonstrated that survival could be different depending on the 
histological type of a certain cancer287. Besides, combining drugs sometimes introduces additive toxicity. 
For example, with the PIE regimen in treating extensive SCLC, the addition of the third agents induces 
myelosuppressions251. Another example is that the combination of Cisplatin with cetuximab and 
pemetrexed has been proved to have a higher rate of drug-related deaths316. Though the initial hope is to 
reduce the dose and toxicity from each individual agent, it is not surprising that additive toxicity is 
observed in some combinations if all agents are toxic.  
    To achieve the best chemotherapeutic effect of a combination, the dosing of each agent is crucial, 
which involves the balance between maximizing efficacy and minimizing toxicities. Taking the 
combination of Cisplatin and topoisomerase inhibitors as an example, the commonly used dose of 
Cisplatin is 80-100 mg/m2, and that of a topoisomerase inhibitor is 0.4 mg/m2/d. While in the combination 
of Cisplatin and belotecan255, the dose of Cisplatin is 60 mg/m2 and that of belotecan is 0.5 mg/m2/d. The 
reason for lowering the dose of Cisplatin is to reduce its toxicity. The increase of the dose of belotecan is 
due to the fact that belotecan as a single agent has been proved highly active against SCLC. On the other 
hand, possible increase of hematologic toxicity of this combination is the primary concern. 
    Efforts, money, time, and hundreds of lives of patients are all used in each clinical trial. The trials to 
compare the chemotherapeutic effect of two different combination regimens often result in no or only a 
little improvement of several months more survival. Combinations including “similar anti-cancer agents” 
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sometimes give different results. It seems like there is chance behind the mechanisms. Likely the low 
success rate of combination designs is due to the poor understanding of each agent in a combination.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  43 
1.7 Project Motivation and Theory: A Novel Combination Chemotherapy of 
Cisplatin and Rhodamine-B 
Although Cisplatin-based cancer treatment has achieved success in the clinic, our understanding of its 
activity is not deep enough. The inaccurate and incomplete understanding of the great anti-cancer drug 
Cisplatin prevents patients from taking the most advantage of it. Here we are going to propose a Cisplatin-
based combination chemotherapy regimen based on its precise mode of action.  
 
1.7.1 Understanding of Cisplatin’s Anticancer Activity 
In this section, a brief review of the current research status of Cisplatin and its anticancer activity will be 
given. In particular, molecular processes taking place before Cisplatin molecules bind to the DNA will be 
emphasized.   
 
1.7.1.1 Cellular Response to Cisplatin 
Before entering the cell, Cisplatin molecules react with proteins like serum albumin321; as a result, its 
bioavailability is limited by the extracellular environment. Cisplatin enters the cell by both passive 
diffusion322 and active transport323, including carrier-mediated import via OCTs (organic cation 
transporters) and Ctr1 (copper transporter 1), and endocytosis321. Once entering the cell, only 1% of 
intracellular Cisplatin molecules can reach the nuclear DNA324. The majority of Cisplatin molecules react 
with other cellular biomacromolecules. For example, thiol-containing molecules deactivate Cisplatin 
molecules before reaching nuclear DNA325. Among those thiol-containing molecules, glutathione (GSH, 
tri-peptide gamma-glutamyl-cysteine-glycine) is the most important sulfhydryl compound that leads to 
Cisplatin resistance326, as discussed previously.  
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Besides, more recent studies have suggested that mitochondria might be another important target of 
Cisplatin327.  
 
1.7.1.2 DNA Lesions Caused by Cisplatin 
It has been believed that DNA is the major target of 
Cisplatin328. Studies of the mechanism of Cisplatin 
suggest that its anti-cancer activity comes from the 
covalent modification of DNA, which induces distortions 
in the structure of DNA, and finally triggers cell death 
events329.  
 
Competition studies have indicated that Cisplatin 
preferentially reacts with guanine bases330,331. DNA of 
salmon sperm treated by Cisplatin has been quantitatively 
analyzed, showing Cisplatin mainly forms intra-strand 
1,2-GG adducts (60-65%) and intra-strand 1,2-AG 
adducts (20-25%), with the remaining being inter-strand G-G cross-links and intra-strand cross-links 
between non-adjacent G bases332,333. Crystal structure of Cisplatin-DNA adducts and the resultant DNA 
bending and unwinding have been demonstrated by x-ray crystallography study334, as shown in Figure 1-
8. The structure of these adducts has also been verified by NMR study335. Furthermore, other studies have 
suggested that Cisplatin-DNA adducts are recognized by high-mobility group (HMG) containing 
proteins336,337, which shield the repair of DNA cross-links via the nucleotide excision repair (NER) 
pathway338,339, as introduced in Section 1.4.2.2.  
					
 
Figure 1-8: Cisplatin-DNA cross-links334. 
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1.7.1.3 Hydrolysis of Cisplatin 
The final products from the interactions of Cisplatin with DNA have been identified, but the molecular 
reactions still need to be investigated. As the structures indicate, before binding to DNA, a Cisplatin 
molecule needs to lose its two chlorine atoms.  
    It has been long believed that an aquation process must occur before Cisplatin molecules can modify 
DNA340. The process involves a sequential replacement of two chlorine atoms by two water molecules. 
The resultant aqua-complexes bind to purines and cause DNA damage332, 334, 341, which blocks cell 
division and results in apoptosis. Cellular biological processes of Cisplatin are shown in Figure 1-9342 and 
the one interferes with DNA is highlighted: 
 
Figure 1-9: Cellular biological processes of Cisplatin342. 
 
    Although the hydrolysis process has been widely accepted, some questions remain unanswered. Dr. Lu 
has challenged this mechanism from different aspects343. First and foremost, this hydrolysis mechanism 
cannot explain the sequence-selective binding of Cisplatin to DNA. Second, the main product of the 
hydrolysis of Cisplatin is [PtCl(H/O) NHF /]Hthat cannot bind to two neighboring guanine bases; while 
the species that can form DNA cross-links, [Pt(H/O)/ NHF /]/H , is very difficult to form under 
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physiological conditions and has been considered “the least important of all the potential hydrolysis 
products available to bind to replicating DNA at pH=7.4” 344,345. Moreover, it has been estimated that the 
rate constant for Cisplatin hydrolysis is only about 10−4 M−1s−1 344, at low Cl− concentrations and a higher 
temperature (45℃), and in solvents such as HClO4 and NaClO4. It is reasonable to infer that the reaction 
rate would be even lower under physiological conditions (37℃ , water environment)344. All these 
considerations indicate that there may exist another mechanism that is responsible for the chloride-bond 
breaks.  
 
1.7.2 DET Mechanism of Cisplatin and Its DET-based Combination Chemotherapy 
In contrast to the conventional approach to synthesize and screen a huge number of Cisplatin-like 
compounds, our group attempted to apply fs-TRLS to unravel the precise molecular mechanism of 
Cisplatin.  
First, Dr. Lu346 discovered the molecular mechanism explaining why low-dose Cisplatin can 
significantly enhance the therapeutic efficacy of radiotherapy, and found that it was due to the extremely 
effective dissociative electron transfer (DET) reaction of Cisplatin with the generated pre-hydrated 
electron ( 𝑒KLMN ): 
𝑒KLMN + 𝑃𝑡(𝑁𝐻F)/𝐶𝑙/ 	 [𝑃𝑡(𝑁𝐻F)/𝐶𝑙/]∗N 	 𝑃𝑡(𝑁𝐻F)/𝐶𝑙 + 𝐶𝑙N 
𝑒KLMN + 𝑃𝑡(𝑁𝐻F)/𝐶𝑙 	 [𝑃𝑡(𝑁𝐻F)/𝐶𝑙]∗N 	 𝑃𝑡(𝑁𝐻F)/ + 𝐶𝑙N 
The resultant cis-Pt(NH3)2 radical very effectively leads to DNA strand breaks346. Second, we showed 
that for chemotherapy, Cisplatin indeed preferentially attracts two electrons from two neighboring 
guanine bases in DNA, since guanine is the most favored electron donor in DNA343: 
𝐺 + 𝑃𝑡(𝑁𝐻F)/𝐶𝑙/ 	 𝐺H + [𝑃𝑡(𝑁𝐻F)/𝐶𝑙/]∗N 	 𝐺H + 𝑃𝑡(𝑁𝐻F)/𝐶𝑙 + 𝐶𝑙N 
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𝐺 + 𝑃𝑡(𝑁𝐻F)/𝐶𝑙 	 𝐺H + [𝑃𝑡(𝑁𝐻F)/𝐶𝑙]∗N 	 𝐺H + 𝑃𝑡(𝑁𝐻F)/ + 𝐶𝑙N 
In contrast, a weaker DET reaction of Cisplatin with DNA base A and no DET reactions with C and T 
were observed. This DET mechanism has uncovered the long-existing mystery of why Cisplatin results in 
a preferential binding of the cis-Pt(NH3)2 to two neighboring G bases in DNA343. Subsequently, this EDT 
mechanism of Cisplatin has been confirmed both experimentally by Kopyra et al. 347 in studying 
dissociative attachments of nearly 0 eV electrons to gas-phase Cisplatin, and theoretically by Kuduk-
Jaworska348 et al. in their quantum chemical studies of the reaction between the pre-hydrated electron (𝑒KLMN )  and aqueous Cisplatin. This new mechanistic insight has great potential to improve existing 
therapies using Cisplatin and enable novel combination treatments for challenging cancers.  
Taking advantage of our discovery of the dissociative-electron-transfer (DET) mechanism of Cisplatin 
as a chemotherapeutic drug343 and its combination with radiotherapy346, we aim to identify effective 
molecular promoters (PMs) to enhance the cytotoxicity of Cisplatin, to overcome the drug resistance, and 
to widen the application of Cisplatin to other cancers such as breast cancer that are insensitive to 
Cisplatin. In view of the extremely high electron reactivity of Cisplatin we hypothesize that the DET 
reaction of an electron-donating agent with Cisplatin will generate the reactive radical and thus enhance 
the cytotoxicity of Cisplatin. Therefore, we have rationally identified several molecular promoters that 
have a high potential to result in a synergistic effect with Cisplatin. Notably, these compounds must be 
electron donors, biocompatible, and essentially non-toxic. A free PMx molecule is expected to react with 
Cisplatin via the DET reaction inside the cancer cell: 
𝑃𝑀𝑥 + 𝑃𝑡(𝑁𝐻F)/𝐶𝑙/ 	 𝑃𝑀𝑥H + [𝑃𝑡(𝑁𝐻F)/𝐶𝑙/]∗N 	 𝑃𝑀𝑥H: 𝐶𝑙N + 𝑃𝑡(𝑁𝐻F)/𝐶𝑙 
The resultant Pt(NH3)2Cl or Pt(NH3)2 (by further reaction with another PM molecule) radical can lead 
to DNA strand breaks346, adding to the intra-strand cross-links induced by Cisplatin alone. It is well 
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known that among various forms of DNA damage the most dangerous is the DNA double-strand break 
(DSBs), which is difficult to repair and is a potent inducer of mutations and cell death. 
We have tested one such compound, tetramethyl-p-phenylenediamine (TMPD), in combination with 
Cisplatin and obtained very encouraging results from measurements of DNA strand breaks, cell viability, 
cytotoxicity, DNA fragmentation, cell cycle checkpoint induction, and apoptosis349. These preliminary 
studies suggest a very promising femtomedicine strategy and strongly motivate us to continue this 
direction of research towards a final goal of developing highly effective combination chemotherapies. 
This novel and innovative approach may offer a highly effective and economical strategy to develop 
combination therapies for use in the clinic.  
TMPD is a well-known biochemical electron donor used in biological system349, but it also shows some 
toxicity. In addition, the enhanced anti-cancer activity relies on its solvent ethanol. These limitations may 
make this combination clinically intolerable and/or ineffective. Thus, our new goal is to find better PMs 
that have no or little toxicity in its “effective concentration range” when combined with Cisplatin.  
1.7.3 Combination Chemotherapy of Cisplatin and Rhodamine-B 
This thesis aims to investigate a novel combination chemotherapy of Cisplatin with Rhodamine-B 
(RDM-B). Oxidation of Rhodamine-B has been well studied in the literature. Particularly, photo-induced 
electron transfer from Rhodamine-B has been discovered350–353. The chemical structure of Rhodamine-B is 
shown in Figure 1-10: 
 
Figure 1-10: Chemical structure of Rhodamine-B 
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And the mechanism for the proposed combination is shown in Figure 1-11: 
 
Figure 1-11 Mechanism of DET-based combination chemotherapy of Cisplatin and Rhodamine-B. 
 
    As the schematic figure shows, Cisplatin can capture two electrons from Rhodamine-B and its two 
chlorine atoms will then leave the molecule; the resultant radical can attack DNA and induce apoptosis.  
This project will perform in-depth in vitro and in vivo studies of the novel combination therapy of 
Rhodamine-B and Cisplatin against various cancers, and will provide spectroscopic evidence of the 
electron transfer reaction between these two molecules. These results will be presented and discussed in 
later Chapters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pt(NH3)2• Apoptosis 
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Chapter 2 
Cisplatin Intrinsically Induce Double-Strand Breaks 
It is well-known that Cisplatin induces cross-links in DNA and they are believed to be responsible for the 
cytotoxicity of Cisplatin. DNA double-strand breaks (DSBs) induced by Cisplatin have been observed but 
were considered to arise from the repair process of DNA cross-links. In this Chapter we investigate the 
formation of Cisplatin-induced DNA DSBs. First we expose human cervical (HeLa) cancer cells to 
Cisplatin and monitor the formation of DNA DSBs by labeling the phosphorylation of histone H2AX, a 
marker of DNA DSBs. Our observations confirm the formation of DNA DSBs in HeLa cells. Second, by 
applying agarose gel electrophoresis, plasmid DNA damage induced by Cisplatin is analyzed. Since no 
repair process could be involved in the extracted and purified plasmid DNA, our results prove that DNA 
DSB could be a result of a direct interaction between Cisplatin and DNA, rather than an intermediate step 
of the repair process of DNA cross-links. 
 
2.1 Introduction 
Cisplatin forms covalent adducts with various cellular macromolecules, while DNA is its principal 
target354. Extensive studies of Cisplatin’s mechanism of action have shown that the cytotoxicity of 
Cisplatin arises from its capacity to damage DNA, by forming Cisplatin-DNA adducts332,334,341: intra-
strand 1,2-d(GpG) adducts (65% of the total adducts) and intra-strand 1,2-d(ApG) (25%) with small 
percentages of 1,3-d(GpNpG) intra-strand cross-links and inter-strand cross-links. Being the major lesion 
induced by Cisplatin, much attention has been given to the formation of DNA cross-links, especially its 
cellular/molecular mechanism.  In contrast, DNA double-strand break (DSB), the most lethal form of 
DNA damage, has not drawn attention in previous studies of Cisplatin. Previous observations have proved 
the formation of DNA DSBs induced by Cisplatin in replicating yeast, E. coli, and in mammalian 
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cells355,356. However, the formation of DNA DSBs were thought to be an intermediate step during the 
repair process of DNA cross-links, rather than a result of direct Cisplatin-DNA interaction.  
    In this Chapter, we show that Cisplatin can intrinsically induce DSBs, by a direct interaction with DNA. 
 
2.2 Experimental Methods 
2.2.1 Chemicals, Cell Lines, Culture Conditions, and Assay Kit 
Cis-Diammineplatinum (II) dichloride used in this study to treat cells and plasmid DNA was purchased 
from Sigma-Aldrich (Sigma-Aldrich Canada Ltd., Oakville, ON, Canada) without further purification. A 
3 mM stock solution of Cisplatin was prepared in ultrapure water (resistivity > 18.2 MΩ/cm, TOC < 1 
ppm) obtained from the Barnstead Nanopure (Thermo Scientific, Dubuque, IA, USA) water system and 
stored in the dark at 4℃.  
    Cell culture minimum essential medium Eagle (MEM) was purchased from Sigma-Aldrich. Penicillin-
streptomycin antibiotics (PS), fetal bovine serum (FBS), phosphate buffered saline (PBS), and trypsin-
EDTA (0.5 g/L porcine trypsin and 0.2 g/L EDTA∙4Na in Hank’s Balanced Salt Solution with phenol red) 
were purchased form Hyclone Laboratories (Logan, UT, USA). The human cervical cancer (HeLa) cell 
line (ATCC#: CCL-2™) was directly obtained from the American Type Culture Collection (ATCC, 
Manassas, VA, USA). HeLa cells were cultivated with MEM supplemented with 10% FBS (v/v), 100 
units/mL penicillin G and 100 µg/mL streptomycin. Cells were incubated at 37℃  in a humidified 
atmosphere containing 5% CO2. 
    HCS DNA Damage Kit used in in vitro DNA double-strand breaks measurements was purchased from 
Invitrogen (Invitrogen, Life Technologies Inc., Burlington, ON, Canada).  
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     Agarose and ethidium bromide (EtBr) used in the gel electrophoresis experiment were purchased from 
Sigma-Aldrich.  
 
2.2.2 DNA Double-Strand Breaks Measurement using the HCS DNA Damage Kit 
DNA double-strand break is the most lethal DNA damage due to its difficulty to repair357. The failure of 
repairing or mis-repairing of DNA DSBs may induce cell death358. Whether or not a treatment can induce 
DNA DBSs is important in evaluating its efficacy. 
    DNA double strand breaks (DSBs) measurements were performed by using the HCS DNA Damage Kit 
(Invitrogen). The main purpose of this kit is to detect and quantitate in vitro genotoxicity, specifically 
DNA DSBs, using pH2AX mouse monoclonal antibodies (1 mg/mL from the manufacturer) to label 
phosphorylated histone variant H2AX, which is involved in the DSB repair process. The visualization is 
achieved by using a secondary fluorescent antibody Alexa Fluor® 555 goat anti-mouse IgG (H+L) (2 
mg/mL from the manufacturer). Another purpose of this kit is to evaluate in vitro cytotoxicity by Image-
iT® Dead Green™ (1 mM in DMSO from the manufacturer) viability staining. Only cells with serious 
injuries are permeable to this DNA-binding dye and therefore be stained. This kit also includes Hoechst 
33342 (10 mg/mL from the manufacturer) nuclear staining. 
    The mechanism is shown in Figure 2-1: 
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Figure 2-1: The detection of DNA double-strand breaks (DSBs) using 𝜸H2AX labeling. 
 
    3000 cells were seeded into 96-well black tissue culture 96-well plates (BD Falcon™) and they were 
allowed an overnight incubation before treatment to ensure that cells had been well attached. At the end of 
the treatment (with 100 µL of cell culture medium), 50 µL of Image-iT® Dead Green™ viability stain 
working solution was added to each well at a final concentration of 0.3 µM. After 30 minutes’ incubation, 
the medium was removed and cells were fixed (100 µL fixative solution, 4% paraformaldehyde (PF), 15 
minutes), permeabilized (100 µL permeabilization solution, 0.25% v/v Triton® X-100 in PBS, 15 
minutes), and blocked (100 µL blocking buffer, 10 mg/mL bovine serum albumin, 1hour), with sufficient 
PBS washing between sequential steps. Then cells were stained with the primary antibody solution (final 
concentration at 1 µg/mL, 1hour), secondary antibody and counterstain solutions (final concentrations at 1 
µg/mL and 1.67 µg/mL, respectively, 1hour, protected from light). After each staining, cells were washed 
3 times with PBS; and 100 µL PBS was added to each well before taking images. Images were taken on a 
Nikon Eclipse TS100/TS100-F microscope with filters set to Ex/Em of BP510-560/LP590 nm for Alexa 
Fluor®, BP330-380/LP420 nm for Hoechst 33342, and BP450-490/LP520 nm for Image-iT® Dead 
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Green™. Exposure time for each fluorophore was set the same for each image. The software ImageJ was 
used to perform quantitative analysis. 
 
2.2.3 Plasmid DNA Gel Electrophoresis  
Agarose gel electrophoresis is a standard method to directly measure plasmid DNA damage. Three 
conformations of plasmid DNA are: intact/supercoiled (SC), relaxed circular with single-strand break 
(SSB), and linear with double-strand break (DSB). This experiment is designed to observe and quantitate 
the amounts of SC, SSB, and DSB DNA after a certain treatment through the DNA migration in an 
agarose gel with an electric potential difference.  
    Agarose gel was prepared by mixing 0.4 g of agarose powder with 4 mL 10× TAE (Tris-Acetate-
EDTA) buffer (48.4 g/L Tris base, 1.14% glacial acetic acid v/v, and 3.7 g/L EDTA disodium salt) and 36 
mL ultrapure water, and heating up the solution using microwave twice for 20 s and 10 s, with a gentle 
shake in between. After the solution was cooled down to 50-60℃, 4 µL ethidium bromide stock solution 
was added (5 mg/mL) to the gel solution to make a final EtBr concentration of 0.5 µg/mL. The apparatus 
is shown below in Figure 2-2: 
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Figure 2-2: Apparatus for plasmid DNA agarose gel electrophoresis. 
 
    As can be seen, it consists of a power supply across the transparent plastic chamber, a small gel box 
placed in the middle of the chamber, a comb used to form DNA loading wells in the gel, and two black 
stoppers to prevent gel solution from flowing out before it is solidified. Gel solution was poured into the 
gel box and allowed for a further cooling to room temperature and to form a solid gel. After the gel was 
solidified, ~250 mL 1×TAE buffer was poured into the chamber and to cover the gel. DNA samples were 
then loaded with 6× DNA loading dye (8 µL DNA sample + 1.6 µL DNA loading dye). DNA molecules 
are negatively charged at a neutral pH, and when the power supply is on, a potential difference is given; 
therefore, DNA molecules will migrate from the cathode to the anode. Their migration speeds in the 
agarose gel are different due to their shape difference and these speeds have the relation SC DNA >DSB 
DNA >SSB DNA. According to the migration speed difference, molecules with different conformations 
can be separated after traveling a certain distance. After being labeled by ethidium bromide that is 
fluorescent under UV radiation, bands of DNA molecules with different shapes (with different damages) 
can be visualized.  
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    Gel electrophoresis experiments in this thesis were all set to the same conditions: 200 ng of DNA per 
well was loaded, 75 V was set for the power supply, DNA molecules were allowed to run for 2 hours 
before images were taken. The gel images were taken on a FluoChem imaging station (Alpha Innotech) 
and the software AlphaEase FC was used to perform quantitative analysis.  
 
2.3 Results 
2.3.1 In Vitro Double Strand Breaks Measurements 
The phosphorylation of histone variant H2AX is the key step in the repair process of DNA double-strand 
breaks (DSB). To study whether Cisplatin could induce DSBs in cells, we detected pH2AX in HeLa cells 
treated with Cisplatin. As is shown in Figure 2-3, after being treated with Cisplatin for 12 h, significant 
DSBs were induced in HeLa cells, which was evidenced from the increased red fluorescence as the 
Cisplatin concentration increased. 
 
Figure 2-3: Representative images of Cisplatin-treated HeLa cells labeled by Alexa Fluor and 
Hoechst 33342 for DNA double strand breaks detection.   
 
 10	µM	CDDP 20	µM	CDDP
30	µM	CDDP 50	µM	CDDP40	µM	CDDP
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Images were merged from those taken at Ex/Em of BP510-560/LP590 nm for Alexa Fluor® (double-
strand break labeling) and those taken at BP330-380/LP420 nm for Hoechst 33342 (nucleic labeling). As 
can be seen from the images, control cells were stained blue. As the concentration of Cisplatin increased, 
more cells were stained pink (merged from red and blue), indicating more double-strand breaks were 
induced in cells. After the concentration reached 30 µM, the percentage of pink-stained cells and their 
brightness did not change significantly, indicating a plateau was reached.  
ImageJ was used to do quantitative analysis: 
 
Figure 2-4: Amount of cellular DNA double-strand breaks in HeLa cells treated with Cisplatin. 
 
2.3.2 Gel Electrophoresis 
To examine whether the formation of Cisplatin-induced DNA DSBs was intrinsic instead of an 
intermediate step during the repair of DNA cross-links, we conducted agarose gel electrophoresis to 
measure damage in plasmid DNA treated by Cisplatin. The gel image and the yields of DNA DSBs in 
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plasmid DNA incubated with Cisplatin at various concentrations for 150 minutes (37 ℃) are shown in 
Figure 2-5 and Figure 2-6, respectively: 
 
Figure 2-5: Picture of the agarose gel of plasmid DNA treated with Cisplatin. 
    DNA DSB yields in each band were determined by calculating the integrated density values. Platinated 
DNA is not visible in the gel image since the fluorescence emission of the DNA-binding dye (EtBr) is 
quenched. It is notable that no DNA repair could be involved in the extracted and purified plasmid DNA, 
this result shows that Cisplatin directly induced DSBs in the plasmid DNA.  
    Quantitative analysis of the gel image is shown in the graph below: 
 
Figure 2-6: Yields of double-strand breaks in Cisplatin-treated plasmid DNA as a function of 
Cisplatin concentration. 
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2.4 Discussion and Conclusion 
Despite the potent anticancer effect of Cisplatin, its application is limited to its severe side effects and 
resistance. Only by accurately knowing the mechanism of Cisplatin could we find ways to overcome its 
limitations. Much attention has been drawn to the cross-links induced by Cisplatin but little to this most 
lethal form of DNA damage, DNA double-strand breaks (DSBs).  
    In this Chapter we confirmed the formation of DNA DSBs induced by Cisplatin in HeLa cells. 
Additionally, we showed evidence that DNA DSBs could be induced by Cisplatin without cellular 
signaling processes; they could be a result from a direct interaction between Cisplatin and DNA, 
independent of the repair process of DNA cross-links. Nevertheless, we do not claim that there is no 
relationship between the formation of DNA DSBs and the repair process of DNA cross-links. Cisplatin 
may induce DNA DSBs via more than one pathway. 
    The relationship between the formation of DNA DSBs and the cellular responses to DNA cross-links in 
cells treated by various compounds/treatments have been reported359–365, it would be of great interest for 
us to further investigate the molecular mechanism of the formation DNA DSBs induced by of Cisplatin 
and other agents.  
    Our observations confirmed that Cisplatin could induce DNA DSBs in human cervical (HeLa) cancer 
cells. More remarkably, our gel electrophoresis experiments showed that these DSBs were induced by 
Cisplatin intrinsically, rather than by an intermediate step during the repair process of DNA cross-links, 
since no repair process could take place in the extracted and purified plasmid DNA in this experiment. 
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Chapter 3 
In Vitro Studies of the Combination of Cisplatin and Rhodamine-B 
3.1 Objective of This Chapter 
Before a new drug can be used to treat patients in the clinic, it takes an average time of 12-15 years and a 
mean cost of about $1.8 billion from its discovery366. The process consists of basic research, preclinical 
tests, clinical tests, and post-marketing surveillance.  
Figure 3-1 shows an overview of screening assays in early drug discovery366: 
 
Figure 3-1: Scope of this Chapter: compound screening and secondary assays, with the summary of 
early drug discovery screening processes/assays366.  
In this project, rather than to test a newly designed anti-cancer drug, we aim to verify the effectiveness 
of a combination regimen of an FDA-approved anti-cancer drug, Cisplatin. So, instead of target 
validation, the starting point of our studies is compound screening. In this Chapter the results of 
compound screening and secondary assays are presented and discussed. 
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    In Chapter 1 the rationale to combine Rhodamine-B with Cisplatin to treat cancer has been introduced. 
In this Chapter, in vitro cell-based and extracted plasmid DNA-based experiments are performed to test if 
the combination of Cisplatin and Rhodamine-B can enhance the chemotherapeutic effect, as compared 
with Cisplatin monotherapy.  
    Various cancer cell lines: human cervical cancer (HeLa and ME-180), human non-small-cell lung 
cancer (A549), human ovarian cancer (NIH:OVCAR-3), and normal human fibroblast (GM05757) cell 
lines are tested in this Chapter. Cell survival, important cellular processes such as apoptosis and the 
formation of DNA double-strand breaks (DSBs) are studied. Direct damage to plasmid DNA extracted 
from E.Coli is also measured.  
    Questions to be answered in this Chapter include the following:  
(1) Is the proposed combination effective in killing cancer cells? 
(2) Is the proposed combination toxic to normal cells? 
(3) How does the combination kill a cell? 
 
3.2 Materials and Experimental Techniques 
3.2.1 Chemicals, Cell Lines, and Assay Kits 
Rhodamine-B (RDM-B) and cis-Diammineplatinum(II) dichloride (Cisplatin, CDDP) used in the current 
study were purchased from Sigma-Aldrich (Sigma-Aldrich Canada Ltd., Oakville, ON, Canada) without 
further purification. A 3 mM stock solution of Cisplatin and a 24 mM stock solution of Rhodamine-B 
were both prepared in ultrapure water (resistivity > 18.2 MΩ/cm, TOC < 1 ppm) obtained from the 
Barnstead Nanopure (Thermo Scientific, Dubuque, IA, USA) water system and stored in the dark at 4℃. 
Cell culture media, including minimum essential medium Eagle (MEM), nutrient mixture F12 Ham 
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Kaighn’s modification (F-12K), Mccoy’s 5A Medium Modified, and RPMI-1640 medium were purchased 
from Sigma-Aldrich. Penicillin-streptomycin antibiotics (PS), fetal bovine serum (FBS), phosphate 
buffered saline (PBS), and trypsin-EDTA (0.5 g/L porcine trypsin and 0.2 g/L EDTA∙4Na in Hank’s 
Balanced Salt Solution with phenol red) were purchased form Hyclone Laboratories (Logan, UT, USA). 
Human cervical cancer HeLa cell line (ATCC#: CCL-2™), human cervical cancer ME-180 cell line 
(ATCC#: HTB-33™), human non-small-cell lung cancer A549 cell line (ATCC#: CCL-185™), and 
human ovarian cancer NIH:OVCAR-3 (ATCC# HTB-161™) cell line were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA, USA) directly. Human skin diploid fibroblast GM05757 
cell line was obtained from the Coriell Cell Repository directly. HeLa and GM05757 cells were cultivated 
in MEM supplemented with 10% FBS (v/v), 100 units/mL penicillin G and 100 𝜇g/mL streptomycin. 
ME-180 cells were cultivated in Mccoy’s 5A medium with 10% FBS, 100 units/mL penicillin G and 100 𝜇g/mL streptomycin. The complete growth medium for A549 cells was the F-12K medium with 10% 
FBS, 100 units/mL penicillin G and 100 𝜇g/mL streptomycin. The complete medium for NIH:OVCAR-3 
cells was RPMI-1640 supplemented with 20% FBS, 100 units/mL penicillin G and 100 𝜇 g/mL 
streptomycin. Cells were incubated at 37℃ in a humidified atmosphere containing 5% CO2. 
    MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MW=414 g/mol) and SDS 
(sodium dodecyl sulfate, MW=288 g/mol) used in the MTT cell viability assay were purchased from 
Sigma-Aldrich. A 12 mM MTT stock solution was prepared by dissolving 50 mg of MTT powder in 10 
mL sterile PBS. The SDS-HCl solution was prepared by dissolving 1 g of SDS powder in 10 mL 0.01M 
HCl. Crystal violet and glutaradehyde used in the clonogenic assay were purchased from Sigma-Aldrich. 
The staining solution was prepared at 0.5% (w/v) of crystal violet and 6.0% (v/v) of glutaradehyde in 
ultrapure water. 
 
  63 
    The CellEvent® Caspase-3/7 Green Detection Reagent and the HCS DNA Damage Kit used in the in 
vitro apoptosis detection and DNA double-strand breaks measurement were purchased from Invitrogen 
(Invitrogen, Life Technologies Inc., Burlington, ON, Canada). The Annexin V-FITC Apoptosis Detection 
Kit was purchased from Sigma-Aldrich.  
 
    Agarose and ethidium bromide (EtBr) used in the gel 
electrophoresis experiment were purchased from Sigma-
Aldrich.  
 
3.2.2 Experimental Techniques 
3.2.2.1 MTT Cell Viability Assay 
The MTT cell viability assay is a popular and fast assay that 
measures cell survival/cell-killing efficacy of a given 
treatment through a direct determination of the cell number 
by using standard microplate absorbance readers.  
     
The 96-well plate with different numbers of cells and the plate reader are shown in Figure 3-2. 
    5000-8000 cells were seeded into 96-well transparent tissue culture plates (BD Falcon™, Corning Inc., 
NY, USA). Treatment was given after overnight incubation to ensure that cells had been well attached and 
adapted to the environment. For each well, cell culture medium was replaced after the desired treatment 
Figure 3-2: MTT assay performed in cells in a 96-well 
plate, and the plate reader. 
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time period with 10 µL MTT stock solution with 100 µL regular complete cell culture medium (without 
phenol red). The light-yellow water soluble MTT was reduced by the mitochondria of a living cell to an 
insoluble purple-blue formazan, which was then dissolved in the SDS-HCl solution after 3-4 hours’ 
incubation. After 4-18 hours’ further incubation, the concentration of the solubilized formazan was 
determined by measuring its absorbance at 570 nm with a Multiscan GO microplate spectrophotometer 
(Thermo Scientific, Mississauga, ON, Canada), and the cell number should be proportional to the 
absorbance.  
    The principle of the MTT assay is shown in Figure 3-3: 
 
Figure 3-3: Principle of the MTT assay. 
 
    For all MTT experiments in this thesis at least three replicates were set for any concentration of 
treatment. Cell viability was represented by the percentage of the untreated (control) cells and the error 
bars represented the standard deviations of the replicates.  
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3.2.2.2 Clonogenic Assay 
Clonogenic assay is considered as a more sensitive cell viability measurement assay that was first 
designed to study radiation effects.  
    Cells were uniformly plated onto 100×100 mm tissue culture dishes (Thermo Scientific), and they were 
allowed at least 5 hours’ incubation before treatment to ensure that cells had been well attached. At the 
end of the incubation period, cell culture medium was removed to terminate treatment. Tissue culture 
dishes were washed by sterile PBS, after that fresh complete cell culture medium was added. Cells were 
further incubated for 10-14 days until clones were big enough to be counted.  
    Dishes were washed with PBS before being stained and fixed by crystal violet and glutaradehyde. After 
staining at room temperature for 30 minutes, staining/fixation solution was removed and dishes were 
washed with ice-cold deionized water to remove residual color. When dishes were dried out, clones were 
counted. 50-100 clones per dish were desirable for accuracy.  
    A picture of a six-well tissue culture dish with countable clones is shown in Figure 3-4: 
 
Figure 3-4: Representative picture of a 6-well plate with clones for counting. 
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    For all clonogenic experiments in this thesis, three replicates for each group were set and the cell 
viability was represented by the percentage of the untreated (control) cells, and the error bars represented 
the standard error of the mean (s.e.m.) of the replicates.  
 
3.2.2.3 Apoptosis Detection using the CellEvent® Caspase-3/7 Green Detection Reagent 
staining 
Apoptosis, or programmed cell death, is characterized by distinct morphological alterations and energy-
dependent biochemical mechanisms367. Chemotherapy may induce DNA damage and therefore p-53 
dependent apoptotic death. Caspases are primary mediators of apoptosis; therefore, detecting the 
activation of caspases provides us information on how a cell is killed by a given treatment.  In this project, 
apoptosis detection is performed by using the CellEvent® Caspase-3/7 Green Detection Reagent staining, 
which is a fluorogenic substrate for activated caspase 3/7. A four amino acid peptide (DEVD) is 
conjugated to a nucleic binding dye to form this non-fluorescent and non-DNA binding substrate. In 
caspase 3/7-activated cells, however, the DEVD peptide is cleaved, and therefore the dye is enabled to 
bind to DNA and to produce fluorescence. The absorption/emission peaks of this reagent are 502/530nm. 
The concentration of the CellEvent® Caspase-3/7 Green Detection Reagent is 2.0 mM in DMSO from the 
manufacturer. The principle is shown in Figure 3-5. 
1500-3000 cells were seeded into 96-well black tissue culture 96-well plates (BD Falcon™) and they 
were allowed an overnight incubation before treatment to ensure that cells had been well attached. After 
the incubation with treatment, the old medium was removed and the CellEvent® Caspase-3/7 Green 
Detection Reagent was added with 100 µL fresh complete cell culture medium to a final concentration of 
5 µM (2-10 µM recommended by the manufacturer). After 30 minutes’ incubation, images were taken on 
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a Nikon Exlipse TS100/TS100-F microscope with the filter set to Ex/Em of BP450-490/LP520 nm. 
Quantitative analysis of caspase-activated (apoptotic) cells was performed by the software Image J. 
 
Figure 3-5: Mechanism of the detection of apoptotic cell through CellEvent® Caspase-3/7 Green 
Detection Reagent labeling. 
 
3.2.2.4 Early/Late Apoptosis Differentiation Using the Annexin V-FITC Apoptosis Detection Kit 
by Flow Cytometry 
Apart from Caspase activation, apoptosis is also characterized by morphologic changes, including the loss 
of cell membrane asymmetry and attachment, blebbing, cytoplasm and nucleus condensation, and DNA 
fragmentation367. In cells undergoing early apoptosis, one important feature is the loss of membrane 
asymmetry. In “healthy” cells, an enzyme, aminophospholipid translocase, helps to locate phospholipid 
phosphatidylserine (PS) to the inside of the cell membrane368. In apoptotic cells, the membrane PS 
translocates itself from the inner leaflet to the outer of the cell membrane. Therefore, apoptotic cells can 
be detected by labeling the external cellular environment-exposed PS. Annexin V is a phospholipid-
binding protein (in the presence of calcium)369,370, with a high affinity for PS. In this kit, Annexin V is 
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conjugated with the fluorochrome fluorescein isothiocyanate (FITC) so that by detecting the fluorescence 
signal of FITC, early apoptotic cells can be identified. Late apoptotic cells undergo the loss of membrane 
integrity. In this kit, a vital dye propidium iodide (PI) is used as a marker of late apoptosis: only dead 
and/or damaged cells are permeable to PI. Therefore, after performing this double staining process, with 
fluorescent microscopy/flow cytometry, cells can be visualized: “healthy” cells will be stained both 
Annexin V and PI negative (no external PS exposure with intact membrane), early apoptotic cells will be 
stained Annexin V positive but PI negative (with external PS exposure and intact membrane), late 
apoptotic/dead cells will be stained both Annexin V and PI positive (with external PS exposure and 
damaged membrane), and necrotic cells will be stained Annexin V negative but PI positive.  
In this experiment, fluorescence detection was performed by flow cytometry. Flow cytometry is a 
technique utilizing a flow cytometer (BD FACSAria™ Fusion) to perform optical/fluorescence detection 
of single cells. A typical flow cytometer is composed of five parts: a light source (laser), a flow cell, 
illumination optics, collection optics, and a detection system.  
A simplified schematic is shown below in Figure 3-6: 
 
Figure 3-6: Schematic diagram of a flow cytometer. 
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In this experiment, the laser wavelength was chosen as 488 nm, by which both FITC and PI can be 
excited. According to the DB FACSAria ™ III User’s Guide, the emission spectra of some commonly 
used fluorochromes are shown in the figure below: 
 
Figure 3-7: Fluorescence spectra of some common fluorophores. Spectra of FITC and PI are 
indicated by red arrows.   
 
As can be seen from the spectra, fluorescence signals from FITC and PI (red arrows) can be well 
separated without significant overlap. Therefore, signals from these two channels can be analyzed 
individually without interfering with one another.  
5×10a cells were seeded into T25 flasks, allowing an overnight incubation to ensure cells had been 
well attached. Treatment was given when cells reached 50% confluence. After the treatment incubation, 
cells were collected (including floating cells in the cell culture medium) by trypsinization. After being 
centrifuged, cells were washed 3 times with PBS and resuspended in 500 𝜇L binding buffer. Then cells 
were labeled by 5 𝜇L Annexin V FITC conjugate and 10 𝜇L PI solution. After ten minutes of incubation 
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protected from light, cells were analyzed by a flow cytometer. In each experiment, one unstained sample 
(without treatment and without any staining) and two positive samples (FITC only and PI only) were 
prepared to help with gating. Quantitative analysis was performed by the software FlowJo to detect 
apoptotic cells.  
 
3.2.2.5 Double-Strand Breaks Measurement Using the HCS DNA Damage Kit 
The experimental method of using DSC DNA Damage Kit to measure in vitro DNA double-strand breaks 
(DSBs) has been described in Chapter 2. 
 
3.2.2.6 Plasmid DNA Gel Electrophoresis  
The experimental method of applying gel electrophoresis to study strand breaks of plasmid DNA in E. 
Coli. has been described in Chapter 2. 
 
3.3 Experimental Results 
3.3.1 In Vitro Cytotoxicity and Toxicity Studies of Rhodamine-B 
The in vitro cytotoxicity and toxicity were studied using the MTT cell proliferation assay. Cytotoxicity 
study of Rhodamine-B on human cervical cancer (HeLa and ME-180), human non-small-cell lung cancer 
(A549), and human ovarian cancer (NIH:OVCAR-3) cell lines were conducted. Toxicity of Rhodamine-B 
on a normal human skin diploid fibroblast (GM05757) cell line was also tested.  
5000-8000 cells were seeded into 96-well plates, after overnight incubation, old medium was replaced 
by fresh cell culture medium with different concentrations of Rhodamine-B (RDM-B). Cells were all 
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treated for 24 hours before the MTT assay was performed. Concentrations of Rhodamine-B were set the 
same for all tested cell lines: 0 to 80 µM with a 10 µM increment.  
The result is shown in Figure 3-8: 
 
    It can be seen that the normal GM05757 cells were almost the least sensitive to Rhodamine-B 
treatment. In contrast, cancer cells especially A549 and NIH:OVCAR-3 cells were highly responsive.  
This MTT viability test shows that Rhodamine-B selectively killed more cancer cells than normal cells, 
which makes Rhodamine-B an ideal candidate for our electron-transfer-based combination with Cisplatin.  
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Figure 3-8: Toxicity and cytotoxicity profiles of Rhodamine-B. Drug-dose response curves obtained 
from MTT assay in GM05757, HeLa, ME-180, NIH:OVCAR-3, and A549 cells. 
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3.3.2 In Vitro Survival Studies of the Combination of Cisplatin and Rhodamine-B 
First, MTT proliferation assay was performed to test the cell-killing efficacy of the combination of 
Cisplatin and Rhodamine-B. All experiments in this section were designed to compare the survivals of 
cells treated by Cisplatin only and its combination with Rhodamine-B.  
5000-8000 cells were seeded into 96-well plates and allowed for overnight incubation. Cells were 
treated with various concentrations of Cisplatin with/without Rhodamine-B. The concentrations of 
Rhodamine-B for different cell lines were chosen at values that can kill 10-20% of cells by Rhodamine-B 
only. Incubation time for all MTT experiments was 24 hours.  
In HeLa cells, Rhodamine-B was tested at 20 𝜇M and 40 𝜇M, with Cisplatin of 0~40	𝜇M. The MTT 
assay results for HeLa cells are shown below: 
 
Figure 3-9: Drug-dose response for cell survival of HeLa cells treated by Cisplatin and its 
combination with Rhodamine-B. In each graph, the dashed line represents the calculated additive 
survival of the combination of Cisplatin and Rhodamine-B. Data points at 0 µM CDDP represent 
the survivals by the treatment of RDM-B only. 
 
In Figure 3-9, additive or expected survivals were calculated based on the fractional effect method that 
has been introduced in Chapter 1. As we can see from the figures, actual survivals of the combination of 
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Cisplatin and Rhodamine-B were significantly lower than that of the calculated additive. That is to say, 
Cisplatin and Rhodamine-B killed HeLa cells synergistically.  
    MTT survival assay was also performed on three other human cancer cell lines: ME-180, A549, and 
NIH:OVCAR-3. Results for these four cell lines are summarized in Figure 3-10:  
 
Figure 3-10: Drug-dose response curves obtained from MTT assay for cell survival of different 
human cancer cell lines: HeLa, A549, NIH:OVCAR-3, and A549; they were treated with Cisplatin 
and its combination with Rhodamine-B. Blue lines represent calculated additive survivals of the 
combination of Cisplatin and Rhodamine-B.   
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As can be seen from the graphs, in HeLa and ME-180 cells, the observed survival curves were 
significantly lower than that of the additive survivals of this combination. In each graph, multiplying the 
survival at a constant Rhodamine-B concentration only and those at corresponding Cisplatin 
concentrations gave the expected additive survival curve. Strong synergistic effect was observed in 
cervical HeLa and ME-180 cells. In NIH:OVCAR-3 cells, moderate synergy was also observed. In A549 
cells, however, the additive and the observed curves showed no significant difference.  
Second, clonogenic assay was conducted to further confirm the in vitro synergistic effect of the 
combination of Cisplatin and Rhodamine-B. Cells were seeded at numbers sufficient to produce 50-200 
clones. Cells were treated by various of concentrations of Cisplatin with/without Rhodamine-B. 
Incubation time for all clonogenic experiments was set the same as 2 hours. At the termination of the 
treatment, in order to sufficiently remove residual Cisplatin and Rhodamine-B, tissue culture dishes were 
washed with PBS and then fresh medium was added. After that, cells were incubated for 10-14 days for 
cells to form clones. After staining/fixation, clones were counted with the naked eye.  
Clonogenic assay results in semi-log graphs are shown in Figure 3-11.As can be seen from the results, 
strong synergy was observed in A549, NIH:OVCAR-3, and ME-180 cells. At higher concentrations, the 
combination of Cisplatin and Rhodamine-B killed 10 times more cells than Cisplatin only did. Synergy 
was less significant in HeLa cells but also observed.  
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Figure 3-11: Drug-dose response curves obtained from clonogenic assay for cell survival of different 
human cancer cell lines: HeLa, A549, NIH:OVCAR-3, and A549; cells were treated by Cisplatin 
and its combination with Rhodamine-B. All graphs were plotted as semi-log graphs.  
 
After we confirmed the synergistic in vitro cytotoxicity of the combination of Cisplatin and 
Rhodamine-B on cancer cell lines, we needed to determine whether or not this combination would give 
additive/synergistic toxicity. Therefore, the MTT survival assay was performed in normal GM05757 cells 
to answer this question. 
The result is shown in Figure 3-12: 
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Figure 3-12: Drug-dose response curves obtained from MTT assay for cell survival of GM05757 
cells treated by Cisplatin and its combination with Rhodamine-B. 
 
GM05757 cells were treated with 0-50 µM Cisplatin with/without 20 µM and 40 µM Rhodamine-B for 
24 hours. As can be seen from the graph, little additional toxicity was observed. The combination of 
Cisplatin and Rhodamine-B did not kill GM05757 cells as effectively as it did in killing other cancer 
cells. 
3.3.3 In Vitro Apoptosis Detection of the Combination of Cisplatin and Rhodamine-B 
CellEvent® Caspase-3/7 Green Detection Reagent was used to detect in vitro apoptosis in HeLa cells. 
3000 cells were seeded into a black 96-well plate and allowed for overnight incubation. Treatments of 0, 
10, and 30 µM of Cisplatin with/without 10 µM Rhodamine-B were given and the incubation time was 12 
hours. Images were taken after 30 minutes of CellEvent® Caspase-3/7 Green Detection Reagent 
incubation.  
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The images are shown in Figure 3-13: 
 
Figure 3-13: Representative images of HeLa cells treated by Cisplatin and its combination with 
Rhodamine-B labeled by CellEvent® Caspase-3/7 Green Detection Reagent. 
 
These images were merged from pictures taken at Ex/Em of BP450-490/LP520 nm and those taken 
under bright field. Green cells represent Caspase 3/7 activated cells, i.e. apoptotic cells. By comparing the 
two images in the 0 µM CDDP column we can see that Rhodamine-B only almost did not induce any 
apoptotic cells at the concentration of 10 µM. However, when 10 µM Rhodamine-B was combined with 
10 µM and 30 µM Cisplatin, it induced many more Caspase 3/7 positive (apoptotic) cells, compared to 
Cisplatin only.  
Quantitative analyses were performed by counting the number of green (apoptotic) cells and the total 
number of cells in each image, and the result was represented by the percentage of apoptotic cells in each 
image, the graph is shown in Figure 3-14: 
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Figure 3-14: Percentages of caspase 3/7 activated HeLa cells as a function of Cisplatin 
concentration. HeLa cells were labeled by CellEvent® Caspase-3/7 Green Detection Reagent. 
Apoptosis is also characterized by its morphological difference from healthy cells. Images taken under 
bright field are shown in Figure 3-15: 
 
Figure 3-15: Representative pictures of HeLa cells treated by Cisplatin and its combination with 
Rhodamine-B. Pictures were taken using a camera under the microscope. 
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Apoptosis is visually characterized by cell shrinkage and fragmentation into membrane-bound apoptotic 
bodies371, 372. As we can see from above pictures, control cells were expanded, well-attached and well-
shaped with clear boundaries. For cells treated with 10 µM Rhodamine-B, though almost no caspase 3/7 
activated cell was observed, cell shape was changed to some extend (black arrows) without significant 
cell shrinkage. This observation was consistent with previously shown MTT viability result: about 15% of 
HeLa cells were killed after 24 hours’ 10 µM Rhodamine-B treatment. When 30 µM Cisplatin was given, 
cell shrinkage was induced to treated cells; round and brighter cells (due to detachment) were observed 
(blue arrows). The combination of Cisplatin and Rhodamine-B induced many more apoptotic cells (blue 
arrows); furthermore, cell membrane blebbing and smaller cell capsules (red arrows) were observed, 
indicating cell fragmentation. 
3.3.4 In Vitro Double-Strand Breaks Measurement of the Combination of Cisplatin and 
Rhodamine-B. 
In vitro double-strand break measurement was performed using the HSC DNA Damage Kit. This assay 
was done on human cervical cancer (HeLa), human non-small-cell lung cancer (A549), and human 
ovarian cancer (NIH:OVCAR-3) cell lines. For all experiments, 3000 cells were seeded into black 96-well 
plates, after overnight incubation, cells were treated with various concentrations of Cisplatin with/without 
Rhodamine-B for 12 hours before the assay was performed. For HeLa cells, concentrations of Cisplatin 
were 0, 1 µM, and 10 µM, and the concentration of Rhodamine-B was 20 µM. 
First, in vitro genotoxicity induced by the treatment was evaluated by phosphorylated H2AX (γH2AX) 
labeling. Images were merged from those taken at Ex/Em of BP510-560/LP590 nm for Alexa Fluor® 
(double-strand break labeling) and those taken at BP330-380/LP420 nm for Hoechst 33342 (nucleic 
labeling). The images of HeLa cells treated by Cisplatin and its combination with Rhodamine-B are 
shown in Figure 3-16: 
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Figure 3-16: Representative images of HeLa cells treated by Cisplatin and its combination with 
Rhodamine-B using the HCS DNA damage kit. Cells were double stained with Alexa Fluor® 555 
(red) and Hoechst 33342 (blue) 
Red cells were cells that had phosphorylated H2AX (with double strand breaks) labeled. It can be seen 
that 20 µM Rhodamine-B almost did not induce double-strand breaks. 1 µM and 10 µM Cisplatin induced 
DNA DSBs and these damages were dramatically enhanced by combining Cisplatin with 20 µM 
Rhodamine-B. ImageJ software was applied to quantitatively analyze the amount of induced DNA DSBs. 
The result is shown in Figure 3-17: 
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Figure 3-17: Integrated Alexa Fluor® 555 fluorescence intensity per cell as a function of Cisplatin 
concentration in HeLa cells using the HCS DNA damage kit.  
Second, cytotoxicity of this combination was also evaluated using this kit from images taken at BP450-
490/LP520 nm for Image-iT® Dead Green™ staining. Only dead cells allow Image-iT® Dead Green™ 
reagent enter cells through damaged cell membrane and labels the DNA. The concentrations of Cisplatin 
and Rhodamine-B were both 10 µM. 
Images of HeLa cells are shown in Figure 3-18. Green cells represent cells with serious membrane 
damage. It can be seen that 10 µM Rhodamine-B did not affect the cell membrane integrity. Cells treated 
with 10 µM Cisplatin were weakly stained by Image-iT® Dead Green™, and cells treated by 10 µM 
Cisplatin combined with 10 µM Rhodamine-B were very strongly stained, which can be seen from the 
bright green color in these cells. 
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Figure 3-18: Representative images of HeLa cells treated by Cisplatin and its combination with 
Rhodamine-B for cytotoxicity evaluation using the HCS DNA damage kit. Cells were stained with 
Image-iT® Dead Green™. 
ImageJ software was applied to quantitatively analyze the amount of Image-iT® Dead Green™ taken by 
HeLa cells and the result is shown in Figure 3-19: 
 
Figure 3-19: Integrated Image-iT® Dead Green™ fluorescence intensity per cell in HeLa cells treated 
by Cisplatin and its combination with Rhodamine-B using the HCS DNA damage kit. 
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This assay was also performed in human lung cancer A549 cells to measure DNA DSBs and to evaluate 
cell membrane integrity (cytotoxicity). 
    Images are shown in Figure 3-20, followed by the quantitative analysis in Figure 3-21: 
 
Figure 3-20: Representative images of A549 cells treated by Cisplatin and its combination with 
Rhodamine-B for DNA DSBs detection and cytotoxicity evaluation using the HCS DNA damage kit. 
Cells were stained with Alexa Fluor® 555 (red), Hoechst 33342 (blue), and Image-iT® Dead Green™ 
(green). 
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Figure 3-21: Integrated Alexa Fluor® 555 and Image-iT® Dead Green™ fluorescence intensities per 
cell in A549 cells treated by Cisplatin and its combination with Rhodamine-B using the HCS DNA 
damage kit. 
 
This assay was also applied in human ovarian cancer NIH:OVCAR-3 cells to measure double strand 
breaks and to evaluate cell membrane integrity. Images are shown in Figure 3-22, followed by their 
quantitative analyses: 
 
Figure 3-22: Representative images of NIH:OVCAR-3 cells treated by Cisplatin and its 
combination with Rhodamine-B using the HCS DNA damage kit. Cells were stained with Alexa 
Fluor® 555, Hoechst 33342 (blue), and Image-iT® Dead Green™ (green). 
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Figure 3-23: Integrated Alexa Fluor® 555 and Image-iT® Dead Green™ fluorescence intensities per 
cell in NIH:OVCAR-3 cells treated by Cisplatin and its combination with Rhodamine-B using the 
HCS DNA damage kit. 
 
3.3.5 Early/Late Apoptosis and Necrosis Differentiation  
Cisplatin is a known apoptosis inducer, which has been confirmed by our Caspase 3/7-activation 
experiment. This current early/late apoptosis and necrosis differentiation experiment was performed in 
human cervical (HeLa) and human lung cancer (A549) cells using the Annexin V-FITC Apoptosis 
Detection Kit.  
HeLa cells were seeded into T25 cell culture flasks at 5×10a cells/flask. Overnight incubation was 
allowed to make sure cells had been well attached. Cells were treated with 0, 20, and 40 µM Cisplatin 
with/without 20 µM Rhodamine-B. One unstained and two positive controls (PI/FITC single stained) were 
prepared for the purpose of flow cytometer setup. Positive controls were prepared by HeLa cells treated 
by 25	µM of Cisplatin. The Annexin V-FITC Apoptosis Detection Kit was performed on the 9 flasks of 
cells after 18 hours of treatment; the protocol from the manufacturer was followed without modification. 
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Before staining with fluorochromes, collected cells were washed with PBS for 3 times to remove residual 
Rhodamine-B and trypsin as much as possible, to minimize overlapped fluorescence signal with PI. After 
adding the binding buffer, cells were filtered through 70 𝜇𝑚 nylon cell strainers to get rid of cell clumps. 
After that, cells were stained with PI and Annexin V-FITC, and then cells were analyzed by the BD 
FACSAria™ Fusion flow cytometer. Quantitative analysis was performed using the software FlowJo.  
Since two fluorochromes, PI and FITC, were used to stain cells, 2 dimensional graphs were plotted to 
display the staining, and 4 quadrants were used to represent 4 staining combinations: PI−/FITC−, 
PI+/FITC−, PI−/FITC+, and PI+/FITC+. The vertical and horizontal lines used to separate cell 
populations were estimated from the single fluorochromes staining (PI/FITC only) of the two positive 
controls. The graphs are shown in Figure 3-24: 
 
Figure 3-24: (A) and (B): Flow cytometry cell distributions in pre-treated apoptotic HeLa cells 
stained with Annexin V-FITC only (A) and PI only (B). (C): Unstained and untreated HeLa cells. 
(D): Untreated HeLa cells double stained with Annexin V-FITC and PI.  
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For the double stained control sample, the line separating FITC+/− was chosen at 266, and the line 
separating PI+/− was chosen at 59. These two values were used as reference (approximately) in separating 
cell populations in the double-stained treated samples. 
    The graphs of treated samples that were both PI and FITC stained and they are shown in Figure 3-25. 
In these graphs, each dot represents a cell. Dots in Q4 represent healthy cells (FITC− and PI−), dots in 
Q3 represent early apoptotic cells, dots in Q2 represent late apoptotic cells, and dots in Q1 represent 
necrotic cells.  
By comparing the left column graphs (control and Cisplatin only) with the right column graphs (with 
Rhodamine-B), it can be seen that the major population of cells (healthy) in the right column graphs 
moved collectively upwards to the PI-positive direction. This was caused by residual Rhodamine-B inside 
cells, which has overlapped excitation and fluorescence spectra with the fluorochrome PI. Although 
collected cells were washed three times with PBS before staining, Rhodamine-B molecules that had 
entered cells cannot be removed. However, this did not affect the analysis, since the PI-positive 
population determined from the positive control that was single stained with PI located at a value around 
1000, which was much higher than that of the upwards-moved population (lower than 100). Therefore, 
these upwards-moved cells were not PI-positive cells. It is notable that for all samples treated with 
Rhodamine-B, its concentration was fixed at 20 µM, and therefore further upwards-moved cells should be 
considered as necrotic. This observation actually provides evidence that Rhodamine-B can enter the cell 
during incubation and it provides chance for the reaction of Cisplatin and Rhodamine-B to occur inside 
the cell. 
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Figure 3-25: Annexin V-FITC Apoptosis Detection in HeLa cells treated by Cisplatin and its 
combination with Rhodamine-B. Cell populations: healthy (FITC−/PI−: lower-left), early apoptotic 
(FITC+/PI−: lower-right), late apoptotic (FITC+/PI+: upper-right), and necrotic (FITC−/PI+: 
upper-left). HeLa cells were treated by 0, 20, 40 𝝁M Cisplatin with (left column)/without (right 
column) 20 𝝁M of Rhodamine-B. All cells were double stained with Annexin V-FITC and PI.  
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Percentage of cells in different conditions are indicated in the above graphs and are plotted below in 
Figure 3-26 and Figure 3-27: 
 
Figure 3-26: Percentages in 100% stacked graph of HeLa cells in different conditions (healthy, early 
apoptotic, late apoptotic, and necrotic) treated by Cisplatin and its combination with Rhodamine-B. 
 
Figure 3-27: Percentages of early/late apoptotic and necrotic HeLa cells treated by Cisplatin and its 
combination with Rhodamine-B. 
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          As can be seen from the graphs, 20 µM Rhodamine-B did not induce early/late apoptosis and necrosis 
by itself. However, when it was combined with Cisplatin, many more early and late apoptotic cells were 
induced, and so were necrotic cells.  
The same assay was performed in A549 cells treated with 25 µM and 50 µM Cisplatin with/without 20 
µM Rhodamine-B. Results are shown in Figure 3-28. 
    As can be seen from the graphs, 20 µM Rhodamine-B did not induce more apoptotic or necrotic cells, 
compared to the control group. When Rhodamine-B was combined with Cisplatin to treat A549 cells, the 
population of early apoptotic cells increased dramatically. The percentages of late apoptosis and necrosis 
did not change significantly among the control and all treated groups.  
    These results were consistent with that of MTT assay. For short time incubation (12/24 hours), HeLa 
cells were more sensitive to not only Cisplatin but also the combination of Cisplatin and Rhodamine-B, 
compared to A549 cells. That is why we see a clear population migration from early apoptosis to late 
apoptosis/necrosis in HeLa cells, but not in A549 cells. 
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Figure 3-28: Annexin V-FITC Apoptosis Detection in A549 cells treated by Cisplatin and its 
combination with Rhodamine-B. Cell populations: healthy (FITC-/PI-: lower-left), early apoptotic 
(FITC+/PI-: lower-right), late apoptotic (FITC+/PI+: upper-right), and necrotic (FITC-/PI+: 
upper-left). HeLa cells were treated by 0, 25, 50 𝝁M Cisplatin with (left column)/without (right 
column) 20 𝝁M of Rhodamine-B. All cells were double stained with Annexin V-FITC and PI. 
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Percentages of cells in the four quadrants are plotted in the two figures below: 
 
Figure 3-29: Percentages in 100% stacked graph of A549 cells in different conditions (healthy, early 
apoptotic, late apoptotic, and necrotic) treated by Cisplatin and its combination with Rhodamine-B.  
 
Figure 3-30: Percentages of apoptotic/necrotic A549 cells treated by Cisplatin and its combination 
with Rhodamine-B. 
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3.3.6 Plasmid DNA Gel Electrophoresis  
Gel electrophoresis was performed in plasmid DNA from E. Coli to test the direct damage induced by 
Cisplatin and the combination of Cisplatin and Rhodamine-B.  
The major lesion in DNA caused by Cisplatin is thought to be 1,2-d(GpG) intra-strand cross-links, as 
introduced in Chapter 1. It has been shown in Chapter 2 that Cisplatin can also intrinsically induce DNA 
double-strand breaks (DSBs). This experiment is designed to study if the combination of Cisplatin and 
Rhodamine-B can enhance the formation of DNA DSBs in plasmid DNA.  
In this experiment, plasmid DNA (Pgem 3Af(-), 3197kbp) was extracted from Escherichia Coli JM109 
and purified using the GeneJET Plasmid Miniprep Kit (#K0502) (Thermo Scientific). 5 µL frozen (–80℃) 
concentrated E. Coli was added to 50 mL autoclaved LB medium (10 g/L tryptone, 5 g/L yeast extract, 10 
g/L NaCl, and 100 µg/mL Ampicillin sodium salt). E. Coli were allowed 16 hours of growth at 37℃ on a 
shaking plate at 200 r/min before the kit was applied to extract and purify plasmid DNA. The protocol 
from the manufacturer was followed without modification.  
DNA samples were prepared in water at a concentration of 25 µg/mL, incubated with 0, 20, 50, 100, 
and 200 µM Cisplatin with/without 10 µM Rhodamine-B. Samples were incubated at 37℃  for 150 
minutes and then the agarose gel electrophoresis was performed on these treated plasmid DNA samples.  
The gel image is shown in Figure 3-31. The amount of DNA in each band on the image was determined 
from the band peak area. The yields of the undamaged DNA and DNA with DSBs, as functions of 
Cisplatin concentration, are presented in Figure 3-32.  
  94 
 
Figure 3-31: Gel electrophoresis image of plasmid DNA treated with 0, 20, 50, 100, and 200	𝛍M of 
Cisplatin with (right)/without (left) 10𝛍M of Rhodamine-B. Three separated bands from top to 
bottom represent DNA molecules with single-strand breaks (SSB), double-strand breaks (DSB), and 
supercoiled (SC) DNA. The gel image seemed over exposed, as the ratios of SSB to SC at 0	𝛍M 
CDDP appeared to be large. 
As shown in Figure 3-32, the presence of Rhodamine-B increased the DNA DSB yields by 
approximately three times, compared to that by Cisplatin only. Due to the fact that CDDP-DNA adducts 
formed from intra-strand cross-linking were invisible in the gel image (the fluorescence emission of the 
DNA-binding EtBr was quenched), the amount of SC DNA decreased as the concentration of Cisplatin 
increased.  
Interestingly, as shown in Figure 3-32 (B), compared to Cisplatin only, the amount of intact (SC) 
plasmid DNA was increased by the addition of Rhodamine-B. That indicates decreased formation of 
Cisplatin-DNA cross-links; it further suggests that Cisplatin molecules were involved in other reactions 
and therefore fewer free Cisplatin molecules were available to bind to DNA. Moreover, the increased 
DNA double-strand breaks should be induced by the product(s) from the reaction between Cisplatin and 
Rhodamine-B, that is, the Cisplatin radicals.   
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Figure 3-32: Amounts of DNA molecules with DSBs (A) and intact supercoiled DNA (B) treated by 
Cisplatin and its combination with Rhodamine-B as functions of Cisplatin concentration.  
 
 
3.4 Conclusion 
This Chapter aimed to verify the effectiveness of the combination of Cisplatin and Rhodamine-B in 
treating various cancer cells.  
    The in vitro chemotherapeutic effect of the combination of Cisplatin and Rhodamine-B was studied 
through cell survival assays, MTT assay and clonogenic assay. Our results strongly supported that the 
cell-killing efficacy of Cisplatin was dramatically enhanced by the addition of Rhodamine-B on various 
cancer cell lines. However, the cell survival was not significantly affected by the addition of Rhodamine-
B on the normal GM05757 cell line. Survival assays showed that our combination had a level of 
selectivity between cancer cell lines and the normal cell line. 
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Cellular processes leading to the death of cancer cells were studied by several experiments: 
immunofluorescence microscopy, flow cytometry, and DNA gel electrophoresis. DNA gel electrophoresis 
directly showed that by adding Rhodamine-B, more double-strand breaks were induced by Cisplatin. 
Caspase 3/7 activation measurement and Annexin V-FITC labeling flow cytometry experiment proved 
that cancer cells were more effectively killed by the combination of Cisplatin and Rhodamine-B via 
inducing more apoptosis. 𝛾H2AX staining demonstrated that by the addition of Rhodamine-B, Cisplatin-
induced DNA double-strand breaks were greatly enhanced.  
To conclude, our studies in this Chapter have proved our combination, Cisplatin and Rhodamine-B, 
effective in the ‘compound screening and secondary assays’ step of early drug development, and this 
combination is therefore ready to be tested in vivo. 
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Chapter 4 
In Vivo Studies of the Combination of Cisplatin and Rhodamine-B 
4.1 Objective of This Chapter 
The results from cell/DNA-based in vitro experiments presented in Chapter 3 have encouraged us to 
perform further preclinical studies through in vivo mouse experiments. This is schematically shown in 
Figure 4-1366: 
 
Figure 4-1: Scope of Chapter 4: in vivo analysis of the combination of Cisplatin and Rhodamine-B, 
with the summary of early drug discovery processes/assays366.   
In this Chapter, xenograft mouse models bearing various cancers: lung cancer, ovarian cancer, and 
cervical cancer are developed to test the in vivo anti-cancer effect of the combination of Cisplatin and 
Rhodamine-B. Tumor growth and tumor samples are studied for chemotherapeutic information; serum 
samples and gut samples are tested for toxicity profiles. 
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In this Chapter, questions to be answered are: 
(1) Is the proposed combination effective in tumor inhibition, or even tumor shrinkage? 
(2) How tumor cells are killed in vivo by our combination? 
(3) Does the proposed combination cause any additional in vivo toxicity? 
 
4.2 Experimental Techniques and Methods 
4.2.1 Chemicals, Cell Lines, Assay Kit, Mice and their Conditions 
Rhodamine-B and cis-Diammineplatinum (II) dichloride for in vivo mouse studies were purchased form 
Sigma-Aldrich (Sigma-Aldrich Canada Ltd., Oakville, ON, Canada) without further purification. A 0.5 
mg/mL solution of Cisplatin and a 3.2 g/mL solution of Rhodamine-B were both prepared in sterile saline 
(0.9% Sodium Chloride Injection USP) purchased from Baxter (Baxter Co., Mississauga, ON, Canada) 
and stored in the dark at 4℃. Matrigel used in tumor cell injection was purchased from Sigma-Aldrich. 
    Xenograft mouse models were used to study the in vivo effect of the combination of Cisplatin and 
Rhodamine-B. The models were developed by injecting cultured cancer cells into the left flank in mice. 
Detailed information on the three cancer cell lines used in in vivo studies: human non-small-cell lung 
(A549), human ovarian (NIH:OVCAR-3), and human cervical (ME-180) cancer cell lines and their cell 
culture media with cell growth condition has been introduced in Chapter 3.  
    In vivo apoptosis detection was performed using the DeadEnd™ Colorimetric TUNEL System 
(purchased from Promega, Madison, WI, USA).  
    Female mice with severe combined immunodeficient disease (SCID) aged 6-8 weeks were obtained 
from Charles River Lab. One-week acclimatization was allowed after mice arrived. Mice were allocated 
to 5 mice/cage.  
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4.2.2 Xenograft Mouse Models  
Xenograft mouse models of A549, NIH:OVCAR-3, and ME-180 cells were studied. Here the 
development of the non-small-cell lung cancer (A549) mouse model is introduced in detail and the other 
two models were built following the same procedure.  
A549 cells were cultured in their normal culturing conditions in T75 flasks. Cells were rinsed (PBS), 
trypsinized, centrifuged, and resuspended in completed F-12K cell culture medium before being counted. 
Collected concentrated cell solution was diluted by 100 times, and 75 µL of which was pipetted into the 
Moxi Z™ (ORFLO® Technologies) Mini Automated Cell Counter to be counted. The concentrated cell 
solution was then diluted in completed cell culture medium, in order that after mixing with the same 
volume of Matrigel the final concentration was 5×10f  cells per 100 µL. The mixing process was 
performed in the biosafety cabinet on ice.  
The cell solution was placed on ice and then transferred to the SCID room for injection.  
Before tumor injection, the left flank area of mice was shaved for a better visualization of tumors. Mice 
were injected under anesthesia through Isoflurane inhalation (carried by oxygen). The Central Animal 
Facility (CAF) at the University of Waterloo provided the apparatus, which is shown in Figure 4-2. As 
can be seen from the picture, the anesthesia system consists of a gas supplier connected to two 
compressed gas cylinders (Isoflurane and oxygen), an anesthesia chamber, a fixed nozzle, and two tubes 
from the pre-injection anesthesia chamber and the nozzle that can be switched when mice were transferred 
from the chamber to the nozzle. Mice were ear-notched (numbered) before injection at the nozzle. 100 µL 
cell solution containing 5×10f  of A549 cells was injected in the left flank to each mouse through 
subcutaneous injection.  
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Figure 4-2: Apparatus for mice anesthesia. 
 
Before injection, the Isoflurane pressure (in the chamber) was set to 5% and during the injection it was 
set to 2-2.5%. Oxygen was continuously given before and during the injection at 1 L/min.  
Xenograft mouse models of NIH:OVCAR-3 and ME-180 were built following the same procedure, 
except that the injected cell numbers were different: 6×10f cells per mouse (NIH:OVCAR-3), and 2×10f 
cells per mouse (ME-180). 
 
4.2.3 Chemotherapy Treatment 
Mice with tumor volume reached the desirable starting point of treatment, 200 mm3 for A549 and ME-180 
models and 150 mm3 for NIH:OVCAR-3 model, were randomly allocated into 4 groups: control, 
Cisplatin, Rhodamine-B, and combination groups. For A549 and NIH:OVCAR-3 models, each group had 
7 mice; and for the ME-180 model, each group had 5 mice. The two extra mice from each group in A549 
and NIH:OVCAR-3 models were euthanized 24 hours after the last treatment for acute toxicity analysis. 
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Mice from the control group received saline injection to eliminate the deviation caused by the injection 
itself. All injections were performed as intraperitoneal (IP) injections.  
KMR® powder was purchased from the pet store and it was given to mice as a nutrition supplement 
when necessary. Vetoquinol Laxatone lubricant was purchased from Shoppers and applied to mice to 
ameliorate constipation. Polysporin® original antibiotic cream was purchased from Shoppers to treat 
tumor ulceration.  
 
4.2.4 Tumor Volume Measurement 
Approximately, mice were weighed and tumors were measured three times a week after treatments, and 
twice a week after two weeks after the first treatment (Day 1). The tumor (and surrounding) area was 
shaved before each measurement to eliminate measurement error caused by the fur.  
Tumors were typically ellipsoid, the lengths of the longest axis (L) and that of the axis perpendicular to 
it (W) were measured by calipers. The volume of a tumor was calculated using the well-accepted 
formula373, 374: 
V = L×W/2  
When multiple tumors were observed, the tumor size was calculated as the summation of individual 
small tumors. 
 
4.2.5 In Vivo Apoptosis Detection Using the TUNEL Assay  
DNA is degraded into 180-200 bp fragments before a cell dies, this fragmentation has been verified as a 
component of (late) apoptosis375–377. The DeadEnd™ Colorimetric TUNEL System is designed to label 
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fragmented DNA in situ and therefore it is used to detect in vivo tumor cell apoptosis. TUNEL is short for 
terminal deoxynucleotidyl transferase (TdT) dUTP nick end labeling. 
Two mice from each group were euthanized 24 hours after the last treatment. The tumor and gut tissues 
were persisted in formalin for further analysis. These tissues were sectioned and fixed on glass slides in 
the University of Guelph Animal Health Laboratory and the DeadEnd™ Colorimetric TUNEL System was 
performed in these sections to detect apoptosis.  
In this experiment, some required materials/chemicals were not included in the assay kit. Phosphate 
buffered saline (PBS) was purchased from Hyclone. Hydrogen peroxide, sodium chloride, formalin, and 
DNase I were purchased from Sigma-Aldrich. Ethanol was bought from the ChemStore at the University 
of Waterloo. Coplin jars were purchased from Fisher.  
The experimental procedure is briefly introduced below. 
The tissue sections were prepared as paraffin-embedded sections. Theses tissue sections were 
deparaffinized and rehydrated by being immersed in ethanol with decreasingly graded concentrations: 
100%, 95%, 85%, 70%, and 50%. After being washed with 0.85% NaCl and PBS, tissue sections were 
fixed in 10% buffered formalin. After another wash with PBS, 100 µL Proteinase K solution (20 µg/mL) 
was added on top of the tissue section to make it permeabilized. After 20 minutes’ incubation, tissue 
sections were washed with PBS, and re-fixed in 10% buffered formalin. Slides were washed twice with 
PBS; excess liquid was removed by tapping with Kimwipes. 100 µL Equilibration Buffer was added on 
the slide to cover the tissue, and allowed for 10 minutes’ incubation. At the end of equilibration, 
Kimwipes were used to blot around the equilibrated areas. 100 µL rTdT reaction mix (98 µL Equilibration 
Buffer, 1 µL Biotinylated Nucleotide Mix, and 1 µL rTdT enzyme) was added on the tissues, and they 
were covered by coverslips and then incubated at 37℃ for 60 minutes in a humidified incubator. After the 
incubation, 2×SSC was applied to terminate the reaction, and 0.3% hydrogen peroxide was used to block 
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the endogenous peroxidase. 100 µL Streptavidin HRP (1:500 dilution) was added on tissue sections and 
allowed for a 30 minutes’ incubation. After being washed in PBS, 100 µL DAB solution was added on the 
tissue until a light brown background could be observed (~ 10 minutes). After being rinsed with deionized 
water a few times, slides were ready to be observed under the microscope. Apoptotic cells were stained 
with dark brown color. 
 
4.2.6 In vivo Acute Toxicity Analysis in Xenograft Mouse Models  
Two mice from each group were euthanized 24 hours after the last treatment for acute toxicity study.  
Blood samples were collected through a terminal cardiac puncture in the mice. After 30-60 minutes’ 
upright standing for natural clotting, blood samples were centrifuged for 10 minutes at 6,000 revolutions 
per minute (rpm) using a Mimi centrifuge Sprout™ (Fisherbrand). The supernatant (serum) was collected, 
labeled, and stored in cryovials at −20℃.  
Serum samples were analyzed to study hepatotoxicity and nephrotoxicity.  
    Xenograft mouse models provide useful and reliable information on the hepatotoxicity of a given 
treatment378. Exposure of drugs or xenobiotics may induce the dysfunction or damage of liver, which is 
called hepatotoxicity379.  Serum alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total 
bilirubin (TBL) are all biomarkers of hepatotoxicity380. ALT participates in the metabolism and 
gluconeogenesis of amino acids by catalyzing the reductive transfer of an amino group from L-alanine to 𝛼-ketoglutarate, the products of this reaction are pyruvate and L-glutamate380. When hepatocytes are 
damaged, ALT will be released to the extracellular space and introduced into the circulation system; as a 
result, elevated serum level of ALT will be detected. The serum ALT activity has been considered the 
gold standard to detect liver injury. ALP is an enzyme catalyzing hydrolysis reactions to remove 
phosphate groups from proteins, nucleotides, and alkaloids at an alkaline pH381. Bile can eliminate ALP, 
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but liver damage inhibits the excretion of bile378. As a result, elevated serum ALP level is an indicator of 
hepatobiliary effects and cholestasis (impaired bile glow)382, and it is also a marker of hepatotoxicity. 
Bilirubin is an “orange-yellow pigment derived from senescent RBCs (red blood cells)”383, which is 
moved from the blood to the liver by binding to albumin. After the dissociation on the hepatocytes’ 
membrane, bilirubin is transported into the cell. Bilirubin must be conjugated to form bilirubin 
monoglucuronide and diglucuronide before being excreted to the bile384. Bilirubin test is used to assess the 
liver’s ability to clear endogenous/exogenous substances from the circulation. The level of bilirubin 
indicates how capable the liver is in moving bilirubin into the bile from plasma379. Elevated level of 
bilirubin in serum also serves as a biomarker of cholestasis and hetatotoxicity380.  
Acute nephrotoxicity (renal toxicity) was studied by measuring the serum urea and serum creatinine 
levels. Urea and creatinine are both end products from nitrogenous metabolism, the metabolism of protein 
(mainly dietary) nitrogen, and the catabolism of muscle creatine, respectively385. Both urea and creatinine 
are excreted through glomerular filtration386. When abnormal kidney function occurs, the glomerular 
filtration rate (GFR) is decreased, and therefore less urea/creatinine is removed from the body with urine. 
As a result, an increased serum urea/creatinine is an indicator of renal dysfunction. In this project, urea 
and creatinine levels in mice serum samples were measured to detect possible nephrotoxicity caused by 
our treatment. Nephrotoxicity also causes electrolyte disturbances. In this project, serum electrolytes 
levels were also measured.  
 
4.2.7 Animal Experiments Guidelines and Humane Endpoints 
All animal experiments in this project were performed in agreement with the University of Waterloo’s 
Guidelines for the Care and Use of Animals in Research and Teaching (AUPP #13-30), the Animals for 
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Research Act of Ontario, and the Guide to the Care and Used Experimental Animals for the Canadian 
Council on Animal Care. 
According to the animal experiment protocol, the humane endpoint is reached if any of the following is 
observed: 
1. Bodyweight loss > 20% from the first day of treatment; 
2. Diameter of the longest axis of the tumor > 17mm; 
3. Body condition score (BCS) < 2; 
4. Deep tumor ulceration.  
Mice were euthanized when the humane endpoint was reached.  
 
4.3 Results and Discussion 
4.3.1 Tumor Growth Inhibition/Shrinkage Study 
4.3.1.1 Lung Cancer (A549) Xenograft Mouse Model 
When the tumor volume reached 200 (±20) mm3 mice were randomly allocated into 7/group with 5 for 
tumor growth measurement and 2 for acute toxicity study.  
    Mice in the control group received saline injections. Mice in the Cisplatin group received 3 treatments 
of 2.5 mg/kg Cisplatin, mice in the Rhodamine-B group received 3 treatments of 8 mg/kg Rhodamine-B, 
and mice in the combination group received 3 treatments of 2.5 mg/kg CDDP and 8 mg/kg with 15-20 
minutes between two injections (in the order: Cisplatin, and then Rhodamine-B). All solutions were 
prepared in saline and all injections were IP injections. Treatments were given on days 1, 3, and 5.  
The tumor growth graph is shown in Figure 4-3: 
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Figure 4-3: Tumor growth curves of mice bearing A549 tumors receiving different treatments: 
saline (black), Rhodamine-B (purple), Cisplatin (blue), and Cisplatin combined with Rhodamine-B 
(red). Error bars represent the standard error of the mean (s.e.m.) of measurements on the same 
day in each group. The inset shows the tumor shrinkage observed in the Cisplatin group and the 
combination group. 
    As can be seen from the curves, three 8 mg/kg Rhodamine-B treatments weakly inhibited the tumor 
growth. Three 2.5 mg/kg Cisplatin treatments induced tumor shrinkage (lowest point to ~180 mm3) during 
the treatment period (day 1-5) and it took 3 more days to grow back to the initial volume. Three 
combination treatments induced a more significant tumor shrinkage (lowest point to ~145 mm3) and the 
tumor shrinkage continued for 13 more days after the treatment. Compared to the Cisplatin group, the 
combination group prolonged the tumor shrinkage duration from 8 days to 18 days. The subsequent tumor 
growth curves also showed a dramatic difference between Cisplatin and combination groups. 
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4.3.1.2 Ovarian Cancer (NIH:OVCAR-3) Xenograft Mouse Model 
When the tumor volume reached 150 (±20) mm3 mice were grouped the same as the lung cancer (A549) 
xenograft mouse model.  
The treatment dosages were the same as that of the lung cancer (A549) xenograft mouse model; 
however, instead of 3 treatments, 1 additional was given. Totally 4 treatments were given: each one on 
days 1, 3, 5, and 7.  
The tumor growth graph is shown in Figure 4-4. 
 
Figure 4-4: Tumor growth curves of mice bearing NIH:OVCAR-3 tumors receiving different 
treatments: saline (black), Rhodamine-B (purple), Cisplatin (blue), and Cisplatin combined with 
Rhodamine-B (red). Error bars represent the standard error of the mean (s.e.m.) of measurements 
on the same day in each group. The inset shows the tumor shrinkage observed in the Cisplatin 
group and the combination group. 
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As shown in Figure 4-4, the tumor growth curve of the control group and that of Rhodamine-B 
treatment group increased at almost the same speed and no significant difference was observed. The 
combination 4 ×  [2.5 mg/kg Cisplatin+8 mg/kg Rhodamine-B] treatments induced tumor shrinkage 
during the treatments (Days 1-7) while the 4 ×  2.5 mg/kg Cisplatin treatments did not. After the 
treatment, the averaged tumor volume in the combination group kept decrease (lowest point on day 18 to 
~ 80 mm3, > 45% tumor shrinkage) and it took approximately 25 more days to grow back to the 
treatment-starting volume 150 mm3. The averaged tumor volume in the Cisplatin group unexpectedly 
decreased from day 10 to day 17, the possibility of measuring error on day 14 was not excluded. Even 
though the tumor shrinkage was questionable in the Cisplatin group, the tumor growth inhibition was very 
significant (approximately 15 days before apparent tumor volume increase), compared to the 
control/Rhodamine-B group.  
Photos of mice with tumors were taken on Day 22. They are shown below in Figure 4-5: 
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Figure 4-5: Pictures of mice bearing NIH:OVCAR-3 tumors receiving different treatments.  
As can been seen from the photos, Rhodamine-B did not significantly affect tumor growth; the tumor 
size from the control group and Rhodamine-B only group did not show a big difference. However, when 
Rhodamine-B was combined with Cisplatin, the tumor growth inhibition was greatly enhanced.  
 
4.3.1.3 Cervical Cancer (ME-180) Xenograft Mouse Model 
When the tumor volume reached 200 (±20) mm3 mice were randomly allocated into 5/group for tumor 
growth inhibition study. (Acute toxicity study was performed on the other two models) 
    Treatments were the same as that of lung cancer (A549) xenograft model, but the dose of Cisplatin was 
given at 2.0 mg/kg instead of 2.5 mg/kg. 3 treatments were given on day 1, 3, and 5.  
The tumor growth graph is shown in Figure 4-6. As the figure shows, ME-180 cells were more sensitive 
to the 8 mg/kg Rhodamine-B treatment, compared to the other two models. Tumor growth was inhibited 
by single agent treatment either Rhodamine-B or Cisplatin, with a weak superiority observed in the 
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Cisplatin group. The combination of Cisplatin of Rhodamine-B more significantly inhibited the tumor 
growth. Tumor-volume-tripling (600 mm3) growth time was 12 days of the control group, 16 days of the 
Rhodamine-B group, 17 of the Cisplatin group, and 26 days of the combination group.  
 
Figure 4-6: Tumor growth curves of mice bearing ME-180 tumors receiving different treatments: 
saline (black), Rhodamine-B (purple), Cisplatin (blue), and Cisplatin combined with Rhodamine-B 
(red). Error bars represent the standard error of the mean (s.e.m.) of measurements on the same 
day in each group. The dashed green line represents the tripled volume from day 1, i.e. 600 mm3. 
 
4.3.2 In Vivo Apoptosis Detection in Tumors 
Tumor samples were collected 24 hours after the last treatment and were stored in formalin. Paraffin-
embedded sections were prepared and to be analyzed. After being processed as the procedure described 
previously, slides were observed under microscope and pictures were taken by a Nikon Cloopix 8400 
camera. Apoptotic cells were stained with dark brown color and non-apoptotic cells were stained blue. For 
each slide, at least 4 pictures were taken.  
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Images of NIH:OVCAR-3 tumor samples from mice are shown below in Figure 4-7. 
 
Figure 4-7: Representative TUNEL pictures of tumor sections from NIH:OVCAR-3 tumor-bearing 
mice receiving different treatments. Black arrows and blue stars are used to indicate positively 
stained (apoptotic) cells and tumor structure changes, respectively. 
As can be seen from the pictures, tumor tissues in the control and Rhodamine-B groups were similar: 
cells were uniformly distributed, connection tissues were well shaped, with few cells stained dark brown 
(apoptotic).  
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Tumor tissues from the Cisplatin group had cells stained with dark brown, indicating Cisplatin 
treatment induced in vivo apoptosis in the NIH:OVCAR-3 tumors. Besides, the tumor structure was 
altered by the treatment: cells were no longer uniformly distributed, cell shape changed, and we could 
even observe some “blank” spaces. In the combination group, tumor change was much more significant. 
More cells were stained dark brown, with a lot of cells isolated and condensed. More hollows were 
observed in the tumor tissue; tumor destruction was more severe.  
These pictures were consistent with our tumor volume measurement. The combination of Cisplatin and 
Rhodamine-B more effectively treated NIH:OVCAR-3 tumors through inducing more apoptosis.  
 
4.3.3 In Vivo Apoptosis Detection in the Gut 
Gut samples were processed the same as tumor samples. 
Representative pictures of NIH:OVCAR-3 gut sections are shown in Figure 4-8.  
These pictures showed that Rhodamine-B induced mild gut damage. Cisplatin induced significant gut 
toxicity; however, the addition of Rhodamine-B did not show further gut damage from the pictures. 
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Figure 4-8: Representative TUNEL pictures of gut sections from NIH:OVCAR-3 tumor-bearing 
mice receiving different treatments. Black arrows and blue stars are used to indicate positively 
stained (apoptotic) cells and structure changes, respectively. 
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4.3.4 In Vivo Acute Toxicity Studies 
Cisplatin-induced toxicity has been extensively studied and has been introduced in Chapter 1. Increase in 
serum creatinine and urea, imbalanced electrolytes’ levels have been reported in Cisplatin-treated 
patients387. Though we have observed significant enhancement in tumor growth inhibition and even tumor 
shrinkage by treating mice with the combination of Cisplatin and Rhodamine-B, we need to study whether  
the addition of Rhodamine-B introduces additional toxicity. 
As described previously, two mice from each group were euthanized for serum sample collection. 
Samples were sent to the University of Guelph Animal Health Laboratory for analysis.  
 
4.3.4.1 Hepatotoxicity 
In this test, serum ALT, ALP, and total bilirubin levels were measured to assess acute hepatotoxicity. Two 
different treatment regiments were given for the two xenograft models: A549 and NIH:OVCAR-3. For the 
A549 model, 2.5 mg/kg Cisplatin with/without 8 mg/kg Rhodamine-B were given on day 1, 3, and 5 (3 
treatments in total); however, for the NIH:OVCAR-3 model, the same concentrations of Cisplatin and 
Rhodamine-B were given on days 1, 3, 5, and 7 (4 treatments in total). For each model, serum samples 
from two mice/group were collected and analyzed.  
The serum level for any marker was represented by the average of the two, and the errors represent the 
standard error of the mean (± s.e.m.).  
The results for hepatotoxicity are shown below in Figure 4-9: 
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Figure 4-9: ALT, ALP, and total bilirubin serum levels in mice (bearing A549 and NIH:OVCAR-3 
tumors) 24 hours after treatment. Light-purple rectangles represent normal serum levels. 
 
Normal serum ALT, ALP, and total bilirubin levels are represented by the light-purple rectangles and 
the numbers are also indicated on the graphs. As can be seen, none of the given treatments induced 
significant increase in serum ALT, ALP, or total bilirubin levels; that is to say, no hepatotoxicity was 
induced. It can be confirmed that the addition of Rhodamine-B to the Cisplatin treatment does not induce 
additional hepatotoxicity.  
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    The hepatic Common Toxicity Criteria of the National Cancer Institute (version 2.0) is outlined below 
in Table 4-1: 
 
Table 4-1: Common hepatic toxicity criteria. 
From the measured results, none of the values was out of the normal limits, even for mice in the 
combination group with increased serum urea and creatinine from the NIH:OVCAR-3 xenograft mouse 
model (with 4 treatments).  
 
4.3.4.2 Nephrotoxicity 
In this test, serum urea and creatinine levels were measured to assess acute nephrotoxicity.  
The serum level results were represented by the average of the two mice from each group, and the 
errors represent the standard error of the mean (± s.e.m.).  
The results for nephrotoxicity of the two xenograft models A549 and NIH:OVCAR-3 are shown below 
in Figure 4-10: 
Grade	 Normal	Range	 0	 1	 2	 3	 4	
Description! None! Mild ! Moderate! Severe! Life-threatening or disabling!
Alanine	Aminotransferase	
(ALT)	 20-120	U/L	 WNL	 >ULN-2.5×ULN	
>2.5-5.0×ULN	
	
>5.0-20.0×ULN	
	
>20.0×ULN	
	
Alkaline	Phosphatase	
(ALP)	
	
35-96	U/L	 WNL	 >ULN-2.5×ULN	 >2.5-5.0×ULN	 >5.0-20.0×ULN	 >20.0×ULN	
Bilirubin	 0-15.39	μmol/L	 WNL	 >1-1.5×ULN	 >1.5-3.0×ULN	 >3.0-10.0×ULN	 >10.0×ULN	
CreaJnine	 3.42-15.39	μmol/L	 WNL	 >1-1.5×ULN	 >1.5-3.0×ULN	 >3.0-6.0×ULN	 >6.0×ULN	
Urea	 2.86-11.78	mmol/L	
WNL	=	within	normal	limits;	ULN	=	upper	limit	of	normal	
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Figure 4-10: Serum urea and creatinine levels in mice (bearing A549 and NIH:OVCAR-3tumors) 24 
hours after treatment. Light-purple rectangles represent normal serum ranges. 
 
For the A549 model, all serum urea and creatinine levels fell in the normal ranges. However, for the 
NIH:OVCAR-3 model, an observable increase in both serum urea and creatinine were observed in the 
combination group, compared to the other three groups. Values were still within the normal range, while 
the addition of errors made them fell at the upper limit of the normal ranges. 4 treatments might introduce 
more severe sides effects than 3 treatments.  
 
4.3.4.3 Electrolytes 
The serum electrolytes levels of Na+, K+, Cl-, and the ratio of Na+/K+ were measured and calculated for 
both the A549 and NIH:OVCAR-3 models.  
Results of the A549 model are shown below in Figure 4-11: 
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Figure 4-11: Serum Na+, K+, Cl− levels in mice bearing A549 tumors 24 hours after treatment.  
Results of the NIH:OVCAR-3 model are shown below in Figure 4-12: 
 
Figure 4-12: Serum Na+, K+, Cl− levels in mice bearing NIH:OVCAR-3 tumors 24 hours after 
treatment. 
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4.3.4.4 Physical Toxicity 
Body weight was monitored along with tumor size measurement. Body weight loss is a common side 
effect of Cisplatin, for example in treating head and heck squamous cell cancer (HNSCC)388. Body loss is 
frequently observed in mice studies of Cisplatin389. Here we measure and study the body weight change 
by different treatments in our trials.  
All measured body weights at Day 1 were normalized to 20 grams. In all three graphs, the minimum 
value of weight was set to 10 grams for a better visualization of the change.  
Body weight measurement for the A549 model is shown in Figure 4-13: 
 
Figure 4-13: Body weight measurement of mice bearing A549 tumors. Error bars represent the 
standard error of the mean (s.e.m.). 
As can be seen from the graph, in 60 days, mice in the control group gained body weight gradually, and 
this was also observed in the group of mice receiving Rhodamine-B only treatment. During the treatment 
days (1, 3, 5), mice receiving Cisplatin with/without Rhodamine-B lost weight; their weights started to 
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increase from day 7-10, a few days after the last treatment. In the A549 mouse model, it can be concluded 
that the body weight loss was attributed to Cisplatin, not Rhodamine-B.  
Body weight measurement of the NIH:OVCAR-3 model is shown in Figure 4-14: 
 
Figure 4-14: Body weight measurement of mice bearing NIH:OVCAR-3 tumors. Error bars 
represent the standard error of the mean (s.e.m.). 
Similar trends were observed in the body weight measurement of the NIH:OVCAR-3 model. A slight 
body weight increase was observed in mice receiving Rhodamine-B only treatment. In this model, it is 
notable that the body weight loss during the treatment was more significant than that in the A549 model. 7 
mice were allocated to each group initially; all mice receiving Cisplatin treatment had at least 10% of 
body weight loss. After sacrificing two from each group for acute toxicity analysis, one mouse from each 
of the Cisplatin group and the combination group was sacrificed due to severe body weight loss (endpoint 
reached: 20% body weight loss from day 1). Other mice gradually gained weight after the completion of 
treatment. Long-term results were not obtained for the combination group since one mouse reached 
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endpoint on Day 32, so the following measurements would be of less statistically accurate. From current 
results, mice in the Cisplatin group recovered slightly faster than the combination group did.  
Body weight measurement of the ME-180 model is shown in Figure 4-15: 
 
Figure 4-15: Body weight measurement of mice bearing ME-180 tumors. Error bars represent the 
standard error of the mean (s.e.m.). 
In the ME-180 model, mice in the Rhodamine-B group gained weight faster than the control group, 
especially during days 18 to 27. This significant increase was not observed in the A549 model; mice in the 
Rhodamine-B group of the NIH:OVCAR-3 model showed a similar but much weaker trend. During the 
treatment, neither mice in Cisplatin group nor mice in the combination group lost weight. However, after 
the last treatment, the addition of Rhodamine-B caused mild body weight loss, compared to the Cisplatin-
only treatment.  
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4.4 Conclusion and Discussion 
4.4.1 Conclusion 
In this Chapter, we tested the combination of Cisplatin and Rhodamine-B in three different xenograft 
mouse models developed by different cancer cell lines: one Cisplatin-sensitive, a cervical cancer (ME-
180) cell line, and two Cisplatin-resistant cell lines, ovarian cancer (NIH:OVCAR-3) and lung cancer 
(A549) cell lines. In all three models, the anti-cancer effect of Cisplatin was significantly enhanced. Our 
combination in the two Cisplatin-resistant models showed surprisingly effective results, in both tumor 
volume and shrinkage time. In the acute toxicity analysis, results showed that the addition of Rhodamine-
B did not induce additional toxicity, nor nephrotoxicity nor hepatotoxicity.   
Nephrotoxicity induced by Cisplatin has been extensively studied and is the most important dose-
limiting factor in Cisplatin chemotherapy390, 391. Results from our mouse model studies have confirmed 
that by using the combination of Cisplatin and Rhodamine-B, the dose of Cisplatin can be reduced to 
achieve the same or better chemotherapeutic effect. Figure 4-16 shows that by using our combination, the 
therapeutic window is broadened. Our combination has a better chemotherapeutic effect at the same 
maximum tolerated dose (MTD), which is only determined by Cisplatin, not Rhodamine-B.  
When standard doses are administered, hepatotoxicity is rare in Cisplatin-induced toxicity392. It is 
notable that clinical standard Cisplatin doses are suggested after the therapeutic effects and toxic side 
effects have been balanced. However, effective tumor suppression may require higher doses or repeated 
low-dose treatments of Cisplatin: under both situations hepatotoxicity has been observed. High-dose 
Cisplatin treatment induced hepatotoxicity has drawn great attention393, 394 due to the fact that when more 
aggressive Cisplatin treatment is required, hepatotoxicity becomes a dose-limiting factor. 
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Figure 4-16: Therapeutic effect improvement by the addition of Rhodamine-B to Cisplatin-based 
cancer treatment. 
    We have confirmed that our combination enhances the anti-tumor effect of Cisplatin without inducing 
additional hepatotoxicity, the problem of high Cisplatin dose requirement to treat some cancers can be 
resolved by the combination of Rhodamine-B with Cisplatin at the MTD.   
 
4.4.2 Discussion of the safety of Rhodamine-B as a part of Cisplatin-based combination 
chemotherapy 
    An optimal DET-based combination will be Cisplatin combined with a non-toxic electron-donating 
agent. Therefore, it is necessary to discuss the validity of the combination of Cisplatin and Rhodamine-B 
from the perspective of safety. Rhodamine-B has been extensively applied in industries like paints, 
papers, leather, textiles, and porcelain395. Due to the concern of toxicity, its applications in food and 
cosmetics have been prohibited. Here we give a brief discussion of the side effects induced by 
Rhodamine-B.  
Effectiveness (%) 
Dose 
Therapeutic Effect  
of Cisplatin 
Toxic Effect 
Therapeutic  
window 
Therapeutic Effect  
of Cisplatin+ RDM-B 
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The notion of Rhodamine-B being toxic comes from a report in 2003 on the illegal use of the dye Sudan 
I in food. Now Rhodamine-B has been categorized “potentially both genotoxic and carcinogenic”.    
Reported studies of the toxicity of Rhodamine-B are summarized in the table below: 
Types of 
Toxicity 
Experiments/Administration Result/Conclusion 
Acute 
Toxicity 
Intraperitoneal LD50 in the mouse 144mg/kg396,397 
Human exposure for 26 minutes, acute, 
aerosolized Rhodamine-B 
Irritant effect, all 17 patients resolved 
within 24 hours, no sequellae 
evidenced398 
6-hour incubation of human lip fibroblasts 
in Rhodamine-B 
Collagen synthesis inhibition399 
Allergenicity Not reported 
Chronic/Sub-
chronic Toxicity 
18 months’ diet administration to rats 
Retarded growth in treated rats at 
higher doses; rats in the highest dose 
group died with liver damage in 6 
weeks400 
Genotoxicity 
Rhodamine-B in the Ames test in 
salmonella typhimurium 
Positive, probably attributed to 
impurity401 
Rhodamine-B in the Ames test in 
salmonella and Chinese hamster ovary 
(CHO) cells 
Increased DNA damage; however 
being confirmed mostly from 
impurities from commercial 
Rhodamine-B402 
Rhodamine-B treatment in muntiacus 
muntjac fibroblast cells 
Increased chromosome aberrations403  
Rhodamine-B in the in vivo Ames test  (rat 
liver after treatment) 
Negative: no significant DNA 
fragmentation and no mutagenic 
activity observed, compared to 
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control404  
Rhodamine-B in the Ames test  Negative mutagenic responses405 
Mutagenic activity test of urinary 
metabolites 
Genotoxicity not supported406 
Genotoxicity test in Drosophila 
melanogaster somatic/germ cell lines 
Genotoxicity indicated from positive 
wing-spot test and sex-linked 
recessive lethal test407 
Carcinogenicity 
 
Rhodamine-B diet treatment in rats408 
(Summarized but not individually 
reported) 
 
Increase in thyroid follicular 
adenomas and carcinomas 
Slight increase in astrocytomas and 
brain tumors in males  
Increase in hepatocellular carcinomas 
in females with high dose treatment 
Sub-cutaneous injection of Rhodamine-B 
in rats and mice 
No link between Rhodamine-B 
treatment and tumor development 
concluded 
Reproductive 
toxicity 
Gavage administration of Rhodamine-B in 
rats and rabbits 
No abnormalities observed in the 
fetuses409 (#118, Burnett et al.) 
Diet administration of Rhodamine-B in 
rats 
No reproductive side effects 
observed409 (#119, Pierce et al.) 
Table 4-2: Reported studies of the toxicities of Rhodamine-B. 
     
    By summarizing these reported references regarding the toxicities of Rhodamine-B we can get a clearer 
picture that if Rhodamine-B is safe to be used as a part of a Cisplatin-based anti-cancer regimen. First, the 
reported intraperitoneal LD50 of Rhodamine-B is 144 mg/kg in mice: in contrast, the results of our trials 
have indicated that a dose of as low as 8 mg/kg is sufficient to cause a significant enhancement in the 
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therapeutic efficacy of Cisplatin, remarkably in tumor shrinkage. It is worthwhile to note that in our in 
vivo studies, the used dose of Cisplatin 2.5 mg/kg is 38% of its reported intraperitoneal LD50 dose (6.6 
mg/kg410) and that of Rhodamine-B is only 5.5% of its IP LD50 value. In other words, the effective dose of 
Rhodamine-B in this combination is far lower than that which could induce significant acute toxicity. 
Second, in the seven studies listed of the genotoxicity of Rhodamine-B, the only certain result was 
obtained in Drosophila, with others either negative or false positive due to impurities in commercial 
Rhodamine-B. Moreover, the effect of impurities could not be excluded in the Drosophila study (with 
reported 90% purity407). Third, some of the studies of carcinogenicity have demonstrated the potential 
tumor-inducing effect of Rhodamine-B but some have not. It is notable that in these studies, Rhodamine-
B was administered with diet for 22-29 months408. The observed possible carcinogenicity should be a 
long-term accumulated effect from persistent exposure to the compound. While in our studies, as well as 
in the clinic, chemotherapy is usually given in a very short time period with much longer recovery 
between treatments. For example, in the treatment of bladder cancer, Cisplatin is intravenously given for 
6-8 hours every 4 weeks. Fourth, listed studies have not shown any evidence for reproductive toxicity or 
allerginicity. Finally, another important rationale for the proposed combination is that Cisplatin itself is a 
much stronger carcinogenic agent than Rhodamine-B, and therefore the reduction of the Cisplatin dose by 
the introduction of the latter should be beneficial to the patients receiving the treatment. To sum up, the 
above listed studies of Rhodamine-B do not provide evidence that it cannot serve as a drug because it 
would induce significant/intolerable additional toxicities. In fact, our acute toxicity analysis has shown 
that the administration of Rhodamine-B at the indicated dose does not introduce measurable 
nephrotoxicity and hepatotoxicity in mice. The use of Rhodamine-B combined with Cisplatin is not only 
effective, but also safe under the indicated schedule and dose.  
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Chapter 5 
Spectroscopic Studies of the Reaction between Cisplatin and 
Rhodamine-B 
5.1 Objective of This Chapter 
In this Chapter, we study the mechanism of the reaction between Cisplatin and Rhodamine-B by utilizing 
spectroscopic techniques.  
Questions to answer in this Chapter are: 
(1) Do Cisplatin and Rhodamine-B react with each other? 
(2) Is the observed reaction an electron transfer reaction? 
 
5.2 Transient Absorption Measurements 
5.2.1 Light Absorption 
When light passes through a clear sample, the intensity of light is reduced as a result of absorption. 
Electronic absorption measurement is widely applied in quantitative analysis of an aqueous sample.  
    A fundamental description of light absorption is Beer-Lambert-Bouguer Law; in which Pierre Bouguer 
and Johann Heinrich Lambert discovered the linear relationship between absorbance and sample light path 
length, and August Beer discovered the linear relationship between absorbance and sample concentration. 
This absorption process with mathematical expressions are shown in Figure 5-1: 
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Figure 5-1: Schematic diagram showing light absorption when traveling through a sample. 
Transmittance is defined as: 
𝑇 𝜆 = 𝐼(𝜆)𝐼p(𝜆) 
Absorbance is defined as: 
𝐴 𝜆 = 𝑙𝑜𝑔-t 𝐼 𝜆𝐼p 𝜆 = 𝜀 𝜆 𝑏𝑐 
In the formula, e(l) is the extinction coefficient, b is the distance that light travels through a sample, and c 
is the sample concentration.  
In the current study, we measure absorbance, a simple form that is directly proportional to sample 
concentration, to do analysis.  
Molecularly, absorption occurs when an electron in a molecule absorbs photon(s) from the incident 
light and then is excited. Since molecular energies are quantized, absorption wavelength/frequency is 
certain in a specific environment. An absorption spectrum, which is often plotted as absorbance (A) 
versus wavelength (𝜆), is used to identify/quantify chromophore(s) in a sample411. In addition, the change 
of an absorption spectrum, for example, red/blue shift or absorption peak decrease, can probe interactions 
involving the chromophore(s) or chromophore(s)-containing assemblies411.  
Sample 
concentration 
c 
Incident beam 
I0(λ) 
Transmitted beam 
I(λ)=I0(λ)10-ε(λ)bc 
Optical length 
b 
b 
I(λ) 
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5.2.2 Femtosecond time-resolved pump-probe transient absorption spectroscopy 
The experimental setup for the femtosecond time-resolved pump-probe transient absorption 
spectroscopy is shown in Figure 5-2: 
 
Figure 5-2: Schematic diagram of the experimental setup for femtosecond time-resolved pump-
probe transient absorption spectroscopy. 
In our experiment, a Ti:sappire laser system (Spectra-Physics) that produces 800 nm laser pulses is 
used. The pulse duration is 100-120 fs and the repletion rate is 500 Hz. As can be seen from Figure 5-2, 
two optical parametric amplifiers (OPA) are applied to produce two laser pulses with desired 
wavelengths: a “pump” pulse that initiates a reaction (to excite a molecule or to generate reacting species) 
and a “probe” pulse to monitor the formation and decay of a specific reaction intermediate (excited 
molecules or generated species). The polarization of the pump pulse with respect to the probe pulse is set 
to be at 54.7° (magic angle) to avoid polarization anisotropy. As Figure 5-2 shows, the time delay between 
Microstepping 
motor stage 
M Pump pulse 
L 
fs	laser	
Probe pulse Sample 
M M 
M 
L 
L 
Detector 
Boxcar 
Time Delay 
1µm ~ 3.3 fs 
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these two pulses is controlled by a Microstepping motor stage. A 1 µm optical path difference corresponds 
to a 3.3 fs time difference; in that way, a fs time resolution is achieved. The motion of the motor stage and 
the collection of data are controlled by Labview programs.  
 
5.2.3 Results and Discussion 
5.2.3.1 Transient absorption probing the formation of (pre-)hydrated electrons  
Since we are studying an electron-transfer reaction, first we perform transient absorption measurement to 
probe the formation of (pre-)hydrated electrons.  
Two-photon absorption in the UV region by water molecules generates electrons416. The well-known 
hydrated electron has a broad absorption peaking at 720 nm417. It has been directly observed by time-
resolved femtosecond laser spectroscopy that before a free electron becomes hydrated, it exists as a 
localized state absorbing in the infra-red region and is called the pre-hydrated electron418. The decay 
lifetime of the pre-hydrated electron that has absorption in the infra-red region corresponds to the rising 
(formation) time of the hydrated electron. Hence the reaction of the former can be directly observed by 
monitoring its own decay kinetics or alternatively the formation kinetics of the latter419,420.  In this 
epre−
H2O 
H2O* 
esol−
pump 
@ 266nm 
Figure 5-3: Schematic diagram showing the generation of solvated electron by UV absorption. 
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experiment, aqueous samples were excited at 266 nm (0.2 µJ/pulse), to generate the pre-hydrated electron, 
and its reaction with Cisplatin in the absence/presence of Rhodamine-B was observed by monitoring the 
formation kinetics of the (pre-)hydrated electron that was detected at 800 nm for experimental 
convenience. The mechanism is shown in Figure 5-3. 
The first part of this experiment aims to investigate if Rhodamine-B enhances or reduces the formation 
of hydrated electrons in water. Samples of pure water, 60 𝜇M, and 120 	𝜇M aqueous Rhodamine-B 
solutions were measured. Results are shown in Figure 5-4: 
 
Figure 5-4: Transient absorbance of (pre-)hydrated electrons in water, 60 µM and 120 µM 
Rhodamine-B solutions. 
As can be seen from Figure 5-4, the addition of 60 µM or 120 µM Rhodamine-B led to no change in the 
transient absorbance (i.e., the yield) of the (pre-)hydrated electrons. In other words, Rhodamine-B did not 
generate and did not capture (pre-)hydrated electrons in water.  
The next part is to probe the (pre-)hydrated electrons in solutions of Cisplatin and Cisplatin combined 
with Rhodamine-B. Results are shown in Figure 5-5: 
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Figure 5-5: Transient absorbance of the (pre-)hydrated electron in water, 3 mM Cisplatin, and 3 
mM Cisplatin with 60 µM and 120 µM Rhodamine-B. 
    As can be seen from Figure 5-5, it is very clear that Cisplatin decreased the initial yield of the (pre-
)hydrated electrons at an ultrashort time scale. This is due to the strong reaction of Cisplatin with the 
ultrashort-lived pre-hydrated electron346,420. However, the addition of Rhodamine-B to the Cisplatin 
solution increased the yield of the (pre-)hydrated electrons. Since the result in Figure 5-4 has shown that 
Rhodamine-B neither generates nor captures electrons in water, the observed results in Figure 5-5 indicate 
that Rhodamine-B competed with the pre-hydrated electrons to react with Cisplatin molecules.  
The above transient absorption measurements of the (pre-)hydrated electrons provide evidence that 
there exists a reaction between Cisplatin and Rhodamine-B and it should be an electron-transfer reaction 
between Cisplatin and Rhodamine-B.  
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5.2.3.2 Transient absorption probing the formation of Rhodamine-B radical cations 
To further testify the nature of the observed reaction between Cisplatin and Rhodamine-B, we conducted 
transient absorption measurement to directly probe the formation of Rhodamine-B radical cations. The 
photo-degradation of Rhodamine-B has been extensively studied350,351,412,413. Initial steps of Rhodamine-B 
photo-degradation are Rhodamine-B photo-excitation and one electron oxidization of Rhodamine-B by 
oxygen414. During this process, Rhodamine-B cation radical RDM-B+• is formed and it has been found to 
have absorption at 490 nm350,415. Therefore, by probing the species RDM-B+•  with/without Cisplatin, we 
could obtain information of the reaction between Cisplatin and Rhodamine-B. A standard femtosecond 
(fs) transient absorption measurement was carried out on Rhodamine-B water solutions with/without 
Cisplatin.  
 
Figure 5-6: Transient absorption of Rhodamine-B radical cation RDM-B+• in 3mM Cisplatin 
solution, 10 µM Rhodamine-B solution, and 10 µM Rhodamine-B with 1.5 mM and 3 mM Cisplatin 
solutions. 
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The pump pulse was chosen at 553 nm (0.2  µJ/pulse) that is the absorption peak of Rhodamine-B, and 
the probe pulse was chosen at 490 nm to monitor the formation of RDM-B+•. Since the reaction between 
Cisplatin and weakly-bound electrons is an ultra-fast process that occurs within 1 picosecond (ps)343,346, 
we measured the transient absorption for only ~8 ps after the 0-point. As can be seen in Figure 5-6, in a 10 
µM Rhodamine-B only water solution, the photo-excitation by 553 nm pulses gave rise to the formation 
of RDM-B+•; when 1.5 mM and 3 mM of Cisplatin was added to the 10 µM Rhodamine-B solution, the 
concentration of RDM-B+• was significantly increased in a CDDP-concentration-dependent manner. In 
addition, the presence of Cisplatin accelerated the photo-degradation of Rhodamine-B, which could be 
seen from the increased yield of RDM-B+•. It suggests that in the solution of both Rhodamine-B and 
Cisplatin, Rhodamine-B donated electrons not only to oxygen, but may also to Cisplatin. The reaction 
between Cisplatin and Rhodamine-B is an electron-transfer reaction. 
 
5.3 Conclusion 
In this Chapter, we have investigated the reaction between Cisplatin and Rhodamine-B, through 
femtosecond time-resolved spectroscopic studies.  
First, our femtosecond time-resolved transient absorption measurement of the formation kinetics of the 
(pre-)hydrated electron has shown evidence that Rhodamine-B competes with pre-hydrated electrons to 
react with Cisplatin. A reaction has been observed and the change in (pre-)hydrated electron formation 
suggests that this observed reaction is an electron-transfer reaction. Second, by measuring the transient 
absorption of Rhodamine-B radical cation, it has been found that the addition of Cisplatin enhances the 
photo-degradation of Rhodamine-B. This observation indicates that Rhodamine-B donates electrons to 
Cisplatin and therefore more Rhodamine-B radical cations are produced.  
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These results strongly prove that Rhodamine-B reacts with Cisplatin, and this reaction is an electron 
transfer reaction: 
RDM − B 	 RDM − B∗ +CDDP 	 RDM − B+• + ClN + Pt(NHF)/Cl• RDM − B 	 RDM − B∗ +Pt NHF /Cl• 	 RDM − B+• + ClN + Pt(NHF)/• 
    With the addition of Rhodamine-B, more radicals, Pt(NHF)/Cl• and/or Pt(NHF)/•, are generated to 
induce DNA strand breaks and therefore to cause cell death. The observed in vitro and in vivo 
enhancement in Cisplatin’s anti-cancer effect by its combination with Rhodamine-B is therefore a result 
from the dissociative electron transfer reaction between Cisplatin and Rhodamine-B. 
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Chapter 6 
Conclusions and Future Research 
Though many cancer treatments are emerging, chemotherapy remains one of the most commonly used. 
Cisplatin-based cancer treatment has achieved success in treating various cancers. However, severe 
toxicity and resistance limit its clinical application. To overcome these limitations, a precise 
understanding of the mechanism of Cisplatin is required. In this project, based on the newly discovered 
dissociative electron transfer reaction (DET) mechanism of Cisplatin, we propose the DET-based 
combination chemotherapy: Cisplatin and Rhodamine-B, in which Rhodamine-B is an electron donor, to 
achieve a better chemotherapeutic effect. In this Chapter, a summary of major results presented in this 
thesis is given and possible future research is discussed.  
 
6.1 Conclusions 
6.1.1 DNA lesions induced by Cisplatin 
In Chapter 2, we have discussed DNA lesions induced by Cisplatin. From previous work, researchers 
believe that the major DNA damage induced by Cisplatin is DNA-CDDP cross-link. In both of our 
plasmid DNA gel electrophoresis and γH2AX labeling experiments, DNA double strand breaks (DSBs) 
are detected. Some studies have attributed the formation of DNA DSBs to the repair process of DNA 
cross-links. However, our gel electrophoresis experiment shows that DNA DSBs can be directly induced 
by Cisplatin without any aid of proteins. Therefore, we conclude that Cisplatin can intrinsically induce 
DNA DSBs without the participation of other cellular events.  
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6.1.2 Combination chemotherapy of Cisplatin and Rhodamine-B 
To verify the anti-cancer effect of the proposed combination of Cisplatin and Rhodamine-B, experiments 
have been conducted: in vitro cell-based assays and in vivo xenograft mouse models to test the 
effectiveness of our combination, and spectroscopic studies to investigate the reaction between Cisplatin 
and Rhodamine-B.  
(1) In Chapter 3, a number of in vitro cell-based assays are performed. First, MTT survival assay is 
done on different cell lines to study the toxicity and cytotoxicity of Rhodamine-B. This 
experiment provides a reference on its dosing in its combination with Cisplatin. We surprisingly 
find the tested human cancer cells are more sensitive to Rhodamine-B, than are normal cells. 
Second, MTT and clonogenic assays are conducted on human cervical ME-180 and HeLa, human 
lung A549, and human ovarian NIH:OVCAR-3 cancer cell lines to test if the combination is 
effective in killing these cancer cells. Drug combination is evaluated using the fractional effect 
method and we find Cisplatin and Rhodamine-B kill cancer cells in a synergistic manner. 
Moreover, this combination is not effective in killing normal cells (GM05757). Further assays are 
performed to investigate other cellular processes under our Cisplatin with/without Rhodamine-B 
treatments. Gel electrophoresis and γ H2AX labeling experiments show that by adding 
Rhodamine-B, the amount of DNA DSBs is greatly enhanced. Caspase 3/7 activation detection 
and Annexin-V-FITC labeling flow cytometry experiments show that the observed cancer-cell-
killing enhancement is achieved through inducing more apoptosis.  
(2) In Chapter 4, in vivo xenograft mouse models are developed to investigate if our combination is 
effective in treating mice bearing tumors, as well as to test if this combination induces additional 
in vivo toxicities in mice. Three xenograft models are built: human lung A549, human ovarian 
NIH:OVCAR-3, and human cervical ME-180 cancer models. In these models, tumor growth is 
greatly inhibited by our combination of Cisplatin and Rhodamine-B, compared to that by 
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Cisplatin-only treatment. Moreover, in the A549 and NIH:OVCAR-3 models, our combination 
induces more significant tumor shrinkage. These are remarkable results, which show high 
promise for the potential success of this combination therapy in future clinical trials. In addition, 
acute toxicity analysis on hepatotoxicity and nephrotoxicity is performed. The results indicate that 
our combination does not induce any of these toxicities.  
(3) In Chapter 5, time-resolved femtosecond laser transient-absorption spectroscopic measurements 
are carried out to investigate the nature of the reaction between Cisplatin and Rhodamine-B. By 
probing (pre-)hydrated electrons upon 2-photon UV absorption of water, it is observed that the 
addition of Rhodamine-B increases the concentration of (pre-)hydrated electrons compared to a 
pure Cisplatin solution, which indicates that Rhodamine-B competed with (pre-)hydrated 
electrons to react with Cisplatin. By probing the radical cation RDM-B+• formed in aqueous 
Rhodamine-B solution under photo-excitation, it is found that the addition of Cisplatin 
significantly increases the yield of RDM-B+•, which indicates that Cisplatin captures electrons 
from Rhodamine-B. These transient absorption results show that there exists an electron transfer 
reaction between Cisplatin and Rhodamine-B.  
 
6.2 Future Work 
We have completed a comprehensive in vitro and in vivo study of the proposed combination of Cisplatin 
and Rhodamine-B and the combination has shown high efficacy in improving the therapeutic efficacy of 
Cisplatin against various cancers. This is the first successful example of DET-based combination 
chemotherapy of Cisplatin shown in both in vitro and in vivo experiments. However, in order to better 
demonstrate the electron transfer reaction between these two agents, further time-resolved femtosecond 
laser spectroscopic studies should be conducted. For example, transient fluorescence up-conversion 
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spectroscopic studies may provide more detailed information on this reaction. In addition, it will be 
necessary and important to study the reaction between Cisplatin and Rhodamine-B under hypoxic 
conditions. Hypoxic cell-based experiments are also of interest to deeper understand this combination. 
    Moreover, though our results have shown that Rhodamine-B is a very promising candidate, more 
screenings should be continued to find other agents that might have better performance in enhancing and 
improving the therapy of Cisplatin in the clinic. In these investigations, both experimental studies and 
theoretical structural considerations should be taken into account. These considerations should include the 
level of synergy, toxicity, and selectivity, as well as the kinetics of the electron transfer reaction. 
Furthermore, the effectiveness under hypoxia is another criterion in the selection of the best combination. 
    In addition, the concept of DET-based combination chemotherapy can also be applied in drug delivery 
and targeted therapy to achieve a better chemotherapeutic outcome for cancer patients. 
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